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artery disease. While data suggest TRIB1 is the causal gene for these traits, the mechanisms by which
TRIB1 affects plasma lipids are not fully understood. In these studies, I sought to elucidate the
physiological and molecular mechanism by which TRIB1 affects plasma lipids. Using a Trib1 hepatocyte
specific deletion mouse model (Trib1Δhep), I demonstrated that Trib1Δhep mice have significantly
increased plasma total cholesterol, HDL cholesterol, non-HDL cholesterol, LDL cholesterol and apoB
protein levels, as well as impaired postprandial triglyceride clearance. I also showed that Trib1Δhep mice
have markedly delayed catabolism of LDL-apoB and VLDL-apoB due to significantly decreased Ldlr mRNA
and protein expression. Since TRIB1’s most studied molecular function is the COP1-mediated
ubiquitination and proteasomal degradation the transcription factor CEBPa, I explored if this interaction is
responsible for TRIB1 effects on plasma lipids and LDLR. I demonstrated that hepatic deletion of Cebpa
in Trib1Δhep mice eliminated the effects on plasma lipids, apoB catabolism and hepatic LDLR regulation.
Additionally, I identified the Activating Transcription Factor 3 (Atf3) as a possible novel mechanism linking
TRIB1 to the regulation of LDLR in a CEBPa dependent manner. We also discovered that Trib1 whole body
deletion (Trib1 KO) on a pure C57BL/6 background leads to a highly penetrant neonatal lethal phenotype,
with less than 5% of Trib1 KO mice making to weaning stages. Our studies determined that Trib1 KO
perish between day 0 and day 1 after birth likely due to severely low blood glucose levels. I also
determined that about adult Trib1 KO mouse have decreased fasting glucose levels, and improved
glucose and insulin tolerance. Overall, my studies stablish Trib1 and its regulation of CEBPa as critical
factors in the regulation of multiple metabolic pathways affecting plasma lipids, as well as novel
regulators of the LDLR and glucose metabolism.
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ABSTRACT
FUNCTIONAL CHARACTERIZATION OF TRIB1, A GENE ASSOCIATED WITH MULTIPLE
CARDIOMETABOLIC TRAITS
Katherine Quiroz-Figueroa
Daniel J. Rader

Genetic variants near the TRIB1 gene are significantly associated with plasma lipid traits
and coronary artery disease. While data suggest TRIB1 is the causal gene for these traits,
the mechanisms by which TRIB1 affects plasma lipids are not fully understood. In these
studies, I sought to elucidate the physiological and molecular mechanism by which TRIB1
affects plasma lipids. Using a Trib1 hepatocyte specific deletion mouse model (Trib1Δhep),
I demonstrated that Trib1Δhep mice have significantly increased plasma total cholesterol,
HDL cholesterol, non-HDL cholesterol, LDL cholesterol and apoB protein levels, as well
as impaired postprandial triglyceride clearance. I also showed that Trib1Δhep mice have
markedly delayed catabolism of LDL-apoB and VLDL-apoB due to significantly decreased
Ldlr mRNA and protein expression. Since TRIB1’s most studied molecular function is the
COP1-mediated ubiquitination and proteasomal degradation the transcription factor
CEBPa, I explored if this interaction is responsible for TRIB1 effects on plasma lipids and
LDLR. I demonstrated that hepatic deletion of Cebpa in Trib1Δhep mice eliminated the
effects on plasma lipids, apoB catabolism and hepatic LDLR regulation. Additionally, I
identified the Activating Transcription Factor 3 (Atf3) as a possible novel mechanism
linking TRIB1 to the regulation of LDLR in a CEBPa dependent manner. We also
discovered that Trib1 whole body deletion (Trib1 KO) on a pure C57BL/6 background
leads to a highly penetrant neonatal lethal phenotype, with less than 5% of Trib1 KO mice
making to weaning stages. Our studies determined that Trib1 KO perish between day 0
v

and day 1 after birth likely due to severely low blood glucose levels. I also determined that
about adult Trib1 KO mouse have decreased fasting glucose levels, and improved glucose
and insulin tolerance. Overall, my studies stablish Trib1 and its regulation of CEBPa as
critical factors in the regulation of multiple metabolic pathways affecting plasma lipids, as
well as novel regulators of the LDLR and glucose metabolism.
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CHAPTER 1: INTRODUCTION

Plasma Lipids Regulation and Cardiometabolic Disease Association
Lipids are a diverse group of organic compounds that are grouped together due to their
insolubility in water, and include fats, oils, steroid hormones, and other cellular membrane
components[1-4]. Lipids have an array of biological functions such as energy storage,
phospholipid bi-layer formation, signaling, and transport, which makes them essential for
life [1]. Additionally, cellular lipid composition and systemic lipids are highly influenced by
dietary, environmental, and genetic factors. As lipids are insoluble in water, they are
transported in the circulation in association with proteins in complexes called lipoproteins,
which are complex particles containing cholesterol esters and triglycerides in their center
and surrounded by phospholipids, free cholesterol and apolipoproteins [2, 5]. Lipoproteins
are commonly divided into six classes which are based on size and lipid composition:
chylomicrons, chylomicron remnants, very low-density lipoproteins (VLDL), intermediate
density lipoproteins (IDL), low density lipoproteins (LDL) and high-density lipoproteins
(HDL); organized from higher to lower triglyceride content [5, 6].
These lipoproteins are sub-divided in two additional categories based on the main
apolipoprotein they contain. The first group contains apolipoprotein B (apoB) as their main
protein, which includes chylomicrons, VLDL and their remnant particles, as well as LDL
lipoproteins. The second group contains apolipoprotein A-I (apoA-I) as their key structural
protein, which include HDL lipoproteins [6, 7]. The plasma concentrations of all these
lipoproteins have been broadly studied for many decades and are related to risk or
protection from coronary artery disease (CAD), the leading cause of death worldwide [8],
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and other vascular diseases. CAD is a complex disease characterized by a buildup of
plaque in the walls of coronary arteries which limits the flow of blood to the heart, a process
called atherosclerosis [9]. Many risk factors have been associated with CAD development
and some of the most studied ones include elevated levels of lipoproteins such LDL
cholesterol (LDL-C) and triglyceride-rich lipoproteins (TRLs), which included VLDLs and
Chylomicrons, as well as low levels of HDL-C [8]. Further details on the mechanisms by
which these lipoproteins are produced and metabolized, as well as their associations with
CAD and other metabolic diseases will be discussed below.

VLDL, IDL and LDL Metabolism (Endogenous Lipoprotein Pathway)
The endogenous lipoprotein pathway is activated in the absence of dietary fats in the liver.
In the endoplasmic reticulum of hepatocytes, triglycerides and cholesterol esters are
transferred to newly synthesized apoB-100 to form VLDL lipoprotein particles [10]. VLDL
are triglyceride rich particles that contain apoB-100 as their core structural protein, and
may contain a combination of other apolipoproteins [6]. The early transfer of triglyceride
to apoB-100 is facilitated by the microsomal triglyceride transfer protein (MTP), then VLDL
particles go through a second MTP-independent lipidation step that is necessary for their
proper formation and subsequent secretion [11]. VLDL particles have been broadly
recognized as biomarkers of risk as well as an independent predictors of CAD risk [12].
Apo B-100 and MTP proteins are highly important regulators of lipid metabolism, as
mutations in both have been shown to fail to produce VLDL, which results in improper
secretion and decreased levels of plasma triglycerides and total cholesterol [13, 14].
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After VLDL particles are formed, they are secreted to peripheral tissues where they
interact with lipoprotein lipase (LPL), which mediates the hydrolysis of triglycerides that
are carried in the VLDL particles [15]. This hydrolysis process forms free fatty acids that
provide energy or that can be stored by muscle cells and adipocytes [16]. LPL is
synthesized in muscle and adipocytes and is activated by apo C-II and apo A-V
apolipoproteins [17]. Loss-of-function mutations in LPL, apo C-II and apo A-V can impair
the system’s ability to hydrolyze triglycerides to free fatty acids and can result in marked
hypertriglyceridemia, which is highly associated with CAD [18-20] . There are also known
proteins to inhibit the activity of LPL such as Apo C-III, angiopoietin like protein 3 and 4
(ANGPTL3 and 4) [21-23] and loss-of-function mutations in these genes are associated
increased LPL activity and decreased plasma triglyceride levels [24, 25].
The hydrolysis of triglycerides from VLDL forms intermediate density lipoproteins (IDL),
also named VLDL remnants. VLDL remnants are enriched in cholesterol esters and
acquire apoE from HDL particles, which is crucial for their clearance from the circulation
by interacting with LDL receptors (LDLR) and LDLR related proteins (LRP) in the liver [6,
26, 27]. VLDL remnants can also be further hydrolyzed by LPL to form low density
lipoprotein (LDL). LDL particles are further enriched in cholesterol esters and also contain
apoB-100 as the main apolipoprotein and carry most of the cholesterol in the circulation,
for which they are known to be the lipoproteins with most associated with the development
of CAD and other vascular diseases [5, 28]. LDL consist of a heterogenous spectrum of
particles that vary in size and density that go from large buoyant, intermediate, and small
dense LDLs. It has been broadly demonstrated that small dense LDLs are highly
atherogenic and are seen in association with an array of diseases phenotypes such as
hypertriglyceridemia, obesity, type 2 diabetes and low HDL [29, 30]. Small dense LDLs
3

have lower affinity for the LDLR, resulting in their prolonged accumulation in the circulation
[30]. Their size also facilitates the easy entry to the arterial wall and their strong binding to
intra-arterial proteoglycans, which promotes their entrapment on the artery [31]. Their
entrapment to the arterial wall makes them more prone to oxidation, which increases their
affinity for macrophage uptake and foam cell formation, which and contributes to
atherogenesis [31-33].
Plasma levels of LDL are determined by the rates of LDL production as well as the rates
of LDL clearance, both of which are regulated by hepatocytes [3]. About 70% of plasma
LDL is cleared by hepatocyte LDLR though receptor mediated endocytosis, and the
remainder of LDL is taken up by other receptors such as LRPs and extra-hepatic tissues
[27]. Increased levels of LDLR in hepatocytes leads to the increased clearance of LDL
particles from the circulation and decreased plasma LDL levels and conversely, decreased
hepatic LDLR levels decreases LDL clearance and leads to increased plasma LDL levels
along with increased risk of cardiovascular disease [34]. The original evidence for the
LDLR mediating the clearance of LDL was provided by Drs. Michael Brown and Joseph
Goldstein after studying families with extremely high cholesterol levels and myocardial
infarction (MI) at an early age. They discovered the LDLR gene as the one that mediates
the uptake of LDL particles by the liver, and they showed that these patients inherited lossof-function mutations in the LDLR gene, which led to their high levels of plasma LDL
cholesterol [4].
The expression levels of the LDLR in hepatocytes is highly regulated by cellular
cholesterol content and by the regulation of the sterol regulatory element binding proteins
(SREBPs) [35]. Low cholesterol levels in the cell signal SREBPs to be transported from
the endoplasmic reticulum (ER) to the Golgi where proteases cleave the SREBPs into
4

active transcription factors [36]. Active SREBPs are then transported to the nucleus where
they stimulate the transcription of the LDLR, to induce the uptake of cholesterol, and other
genes such HMG-CoA reductase, which is the rate limiting enzyme in cholesterol
synthesis pathway [36]. When the cellular cholesterol content is high, SREBP proteins
remain inactive in the ER and the synthesis of LDLR is not stimulated. The LDLR is
targeted for proteasomal degradation by E3 ubiquitin ligase inducible degrader of the lowdensity lipoprotein receptor (IDOL) protein [37]. This process happens when the cellular
cholesterol content is too high, which leads to the oxidation of cholesterol. Oxidized sterols
activate the liver X receptor (LXR), a nuclear hormone receptor which stimulates the
transcription of IDOL, which in turns leads to the ubiquitination and degradation of the
LDLR to prevent further cholesterol uptake [38]. Additionally, the LDLR is also regulated
by the Proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9). PCSK9 is
a secreted protein that binds to the LDLR and enhances its degradation in the lysosomes
[39]. PCSK9 loss of function mutations have been shown to increased LDLR activity and
decreased LDL levels while gain of function mutations in PCSK9 decrease LDLR activity
and elevate LDL levels [40].
One of the most broadly used methods to lower plasma LDL cholesterol in humans are
statins, which are HMG-CoA reductase inhibitors. Statins block the active site of HMGCoA reductase, the rate-limiting enzyme in the cholesterol synthesis pathway, which
results in reduced hepatic cholesterol synthesis and leads to increased production of
microsomal HMG-CoA reductase and increased cell surface LDLR expression in the liver
[41-44]. The increase in LDLR levels promotes the clearance of LDL-C from the circulation
and results in reduction in circulating LDL cholesterol levels. The use of statins has
reduced morbidity and mortality associated with CAD by lowering circulating LDL levels;
5

however, many patients remain at high cardiovascular risk despite high dose statin
therapy, and other patients are statin intolerant and cannot achieve normal LDL
cholesterol levels [45-47]. For this reason, a better understanding of the genetic regulation
of LDL and other factors such as triglycerides and how they promote CAD could lead to
the development of novel, or improved treatments for CAD.

Chylomicron metabolism (Exogenous lipoprotein pathway)
The exogenous lipoprotein pathway is activated after food consumption. Postprandial
triglycerides are emulsified by bile acids and then hydrolyzed by intestinal lipases, which
leads to the formation of fatty acids and monoglycerides [48]. The absorbed fatty acids and
monoglycerides are then transported to enterocytes, where they can be re-esterified to form
triglycerides, which are package together with cholesterol esters into chylomicrons

lipoproteins particles in the endoplasmic reticulum [49]. Chylomicrons are larger
triglyceride rich lipoproteins compared to VLDL, and their size is dependent on the amount
and the type of fat ingested and absorbed by the intestine [48]. Chylomicrons and VLDLs
have similar functions, as they both transport dietary triglycerides and cholesterol to
peripheral tissues and the liver. The core structural protein of chylomicrons is apoB 48,
and it is required for their formation in the ER [49]. ApoB 48 is shorter form of ApoB100,
which is incorporated into chylomicrons due to RNA editing that occurs in the enterocytes
but not hepatocytes in certain organisms [50, 51]. In mice, both apoB 48 and apoB 100
are present in hepatocytes [50]. As in VLDL, MTP is also required for the proper lipidation
of the chylomicron particle in the endoplasmic reticulum.
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After chylomicrons are formed, they are secreted to the circulation where they interact
LPL, which results in a smaller lipoprotein particle named chylomicron remnants, which
are further enriched in cholesterol esters and acquire apo E from HDL [5, 17, 49, 52].
Chylomicron remnants are cleared from the circulation by the liver, this mediated by the
binding of Apo E to the LDLR and other hepatic receptors such as LRP and syndecan-4
[5]. Apo E is crucial for the clearance of chylomicron remnants and mutations in this
apolipoprotein can result in decreased chylomicron clearance and increased cholesterol
and triglyceride plasma levels [53, 54].

HDL metabolism (Reverse cholesterol transfer pathway)
HDLs are formed through the secretion of apoA-I, the main structural protein in HDL
particles, which is mainly secreted from the liver and small intestinal enterocytes [5]. After
its secretion, lipid poor apoA-I acquires phospholipids and free cholesterol from cells in a
process that is facilitated by ATP-binding cassette transporter proteins (ABCA1) on the
cell surface [55, 56]. This process allows the nascent apoA I particles to mature into HDLs.
ABCA1 mutations impair the process of lipid transfer to newly secreted apo A-I, which
leads to the rapid catabolism of apo A-I and low levels of mature HDL lipoproteins [57].
HDLs can also acquire phospholipids and cholesterol from other tissues that express
ABCA1 such as muscles cells and adipocytes, and from other lipoproteins such as
chylomicrons and VLDL during the process of hydrolysis by LPL [55]. The transfers of
phospholipids between lipoprotein is mediated by the phospholipid transfer protein (PLTP)
[58].
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To form mature HDL particles, the free cholesterol transferred from cells to the surface of
the HDL need to be esterified to cholesterol ester, a process mediated by the
lecithin:cholesterol acyltransferase (LCAT) enzyme [59]. Patients with LCAT deficiency
present low HDL cholesterol and apo A-I levels and a high levels of small HDL particles in
the circulation [60]. The cholesterol ester in the core of mature HDL particles can then be
exchange for other lipids in a process mediated by the cholesteryl ester transfer protein
(CETP) [61] . Humans with CETP deficiency show very high HDL cholesterol levels and
large HDL particles [61]. HDL particles are susceptible to lipolysis by extracellular lipases
which promote their catabolism and clearance to liver and other tissues via the scavenger
receptor class BI (SR-BI) protein [62].

This process mediates the uptake of HDL

cholesterol without inducing the degradation of the HDL apolipoprotein, apoA I, which is
maintained in the circulation and can mature into large HDL through the subsequent
accumulation of lipids [63]. In contrast to LDL, evidence suggests that high levels of HDL
and the reverse cholesterol transport have an inverse relationship with CAD risk.

Human genome wide association studies (GWAS) are a helpful tool to identify
novel genetic loci for cardiometabolic traits.
One of the main goals of human genetics is to understand and identify risk factors for rare
and complex diseases in the population. Rare diseases follow Mendelian genetics and the
concept of dominant and recessive traits and prior to GWAS it was thought that they were
caused by mutations within one or a few genes; on the other hand, complex diseases and
traits, have been known to be controlled by multiple genes and their inheritance does not
follow mendelian genetics [64]. However, since GWAS came to light, we have discovered
that many traits and diseases, rare and complex, are influenced by hundreds to thousands
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genetic mutations and environmental risk factors [65]. Complex traits such as plasma
lipids, blood pressure, height and body mass index are highly influenced by numerous
environmental and genetic factors which contributes to their high rates of genetic variation
and complicates the determination of the exact genetic contributors for a certain trait [66].
Given the fact that many of these traits highly contribute to disease, there is a lot of interest
in identifying all the genetic contributors to these phenotypes and understanding their
mechanism of action.
One of the most useful technologies used to determine the genetic contributors for
common traits is genome wide association studies (GWAS). GWAS measures and
analyzes DNA sequence variation across the human genome with the goal of identifying
genetic risk factors for diseases that are common in the population [65, 67]. This is
accomplished by using high-throughput technologies that search for millions of genetic
variants across the genomes of thousands of individuals, called single nucleotide
polymorphisms (SNPs), with the goal of identifying genotype to phenotype associations
that occur more frequently in people with a particular disease or trait than in people without
the disease [65, 67, 68]. The results from GWAS can ultimately lead to the prediction of
who is at risk of disease, the discovery of novel genetic biology and the identification of
new preventions and treatments for the specific disease.
In the last two decades, GWAS has identified many genetic factors associated with
common traits and complex diseases and their modifiable causal factors in large
populations, which has revolutionized the field of complex disease genetics. One of
GWAS greatest strengths is that it has been able to confirm previously known genes
associated with specific traits. For example, in the case of plasma lipid levels it was able
to re-discovered LDLR, HMG-CoA, LPL, ApoC, ApoB, Lp(a) and others as mayor
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regulators of plasma lipid levels, this showing that the experiment works as advertised
[69]. GWAS findings also implicate genes of unknown function or genes without previously
known relevance for a certain trait, however their results only present statistical
associations between variants within a genetic loci and traits [68]. In the case of plasma
lipids some novel genetic associations include SORT1, TRIB1, ANGPTL3 and others [69].
For this reason, experimental validation of these loci is required to identify the specific
candidate genes causing the phenotype, which could lead to the discovery of novel
biological mechanisms underlying diseases [70]. For this purpose, genetically modified
mouse models and cell-based assays are ideal systems for investigating the physiological
functions of candidate genes identified by GWAS [68, 71].
Even though GWAS have helped identify a great number of genetic variants associated
with common diseases and traits, this methodology possesses some limitations. GWAS
variants only account for a modest proportion of the estimated heritability of most complex
traits, for which reason they are unable to fully explain the genetic risk of common diseases
[68]. GWAS is also unable to pinpoint the actual causal variants for the specific traits, this
because of local correlation of multiple genetic variants by linkage disequilibrium, which
makes it difficult to identify the specific causal variant [71]. Many GWAS signals map to
non-coding regions of the genome, which complicates interpretation of the biological
significance of the associations [68]. Additionally, GWAS functional validation of causal
genes has been challenging, with only a handful of all GWAS hits being experimentally
validated. Even with these challenges, recent technical advances in genome editing, stem
cells, and high-throughput screening methods combined with rapidly growing genomic
databases are anticipated to accelerate the functional validation of hits from GWAS
studies.
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Although the validation of GWAS hits has been a slow process, there has been several
successes worth mentioning. One of the first successes of GWAS was the identification a
major risk factor for age-related macular degeneration (AMD), the Complement Factor
H gene [72]. They identified DNA sequence variations in this gene the led to its increased
activity and that were associated with disease, additionally, the biological basic of these
effects was validated using knockout mouse models [73, 74]. Another success of GWAS
was the discovery of SNPs in the gene ATG16L1 that pointed toward the role of autophagy
in Crohn’s disease [75]. These SNPs lead to missense mutations and diminished
autophagy under cellular stress, which impaired intracellular bacterial clearance and
increased inflammatory cytokine production, leading to a chronic inflammatory state [76].
Other GWAS studies implicated the gene loci SLC16A11 with Type 2 diabetes (T2D)
through in regulation insulin secretion [77]. Additionally, GWAS studies for obesity,
another common and complex trait have identified the genes Zinc Finger Protein 90
(ZFP90) and Complement C3a receptor 1 (C3AR1) to be implicated in regulating adiposity
[78]. The association of both these genes with the regulation of adiposity has been
validated using transgenic mice and knockout models [78]. These successes show that
there are still a lot of opportunities to uncover and validate more GWAS genetic
associations that could lead to the better understanding and possible therapeutic target
for certain diseases.
Since the introduction of GWAS in the mid-2000, plasma lipids have been some of the
most studied complex traits, this because of their close association with the development
of multiple cardiometabolic diseases. Some of the most studies lipid trait are the levels of
high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C),
total cholesterol and triglycerides. The first GWAS studies for lipid traits were published in
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2008 and consistent of almost 9,000 participants [79, 80]. In these studies, the authors
identified various genes with already known functions in the regulation of plasma lipids,
however, they were also able to identify several novel genetic loci associated with the
regulation of plasma lipid traits. For the regulation of LDL-C they identified 2 main gene
loci: the SORT1/CELSR2/PSRC1 gene locus as well as the NCAN/CILP2/ PBX4 gene
locus. The GALNT2 gene locus and MVK/MMAB gene locus were identified for the
regulation of HDL-C; and the TBL2, MLXIPL, TRIB1, and ANGPTL3 gene loci were
identified for regulation of triglyceride levels [79, 80]. Since the original GWAS reports,
several follow-up studies and metanalyses have validated these original findings and have
identified many new loci associated with at least one lipid trait [81-85]. Also, several groups
have validated the association of some of these loci with plasma lipid metabolism using
cell and mouse models.
Since the first lipid GWAS studies, follow up studies were able to increase the number of
participants, which have allowed for the determination of more loci associated with lipid
traits. In 2013, the Global Lipids Genetics Consortium (GLGC) reported a GWAS for all
mayor lipid traits, which included total cholesterol, HDL-C, LDL-C and TG, as well as CAD
incidence [69]. The GLGC studies were performed in about 196,000 participants and
included individual of European and non- European decent and identified 95 genetic loci
associated with plasma lipid traits and CAD, of which 59 were novel associations with
unknown roles in plasma lipid regulation [69]. Of the 95 genetic loci associated with plasma
lipid traits, only 4 loci were associated with all major lipid trait as well as the incidence of
CAD in different populations. These loci were within the associated interval of the CETP,
FADS1,2,3, APOA1 and TRIB1 genes, with TRIB1 being the only one with no previous
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known association to plasma lipid metabolism and CAD [69]. These findings made TRIB1
a very interesting candidate for novel studies regarding plasma lipid association and CAD.
More than 200 genetic loci have been associated with multiple lipid traits, which has
provided with an array of targets for study lipid metabolism as well as possible therapeutics
targets for cardiometabolic diseases [69, 80-86]. The last few years our laboratory has
been interested in exploring the possible physiological and molecular mechanism by which
several plasma lipid GWAS signals regulate blood lipids. My thesis project further
contributes to this goal by characterizing the novel GWAS hit TRIB1 and its effects on the
regulation of lipid metabolism and cardiometabolic traits.

The TRIB1 Locus

Tribbles Discovery in Drosophila Melanogaster
The Tribbles family of proteins was first identified in the fly species Drosophila
Melanogaster as a regulator of cell division and morphogenesis. In the 2000’s several
studies described Drosophila Tribbles as a novel regulator of String in morphogenesis, is
the fly orthologue of mammalian cdc 25, a phosphatase that regulates cell cycle
progression [87]. Two independent studies identified Tribbles as a novel gene required for
delayed mitosis during the formation of Drosophila ventral furrow, a key morphogenetic
event that leads to the internalization of mesodermal precursors during gastrulation [8890], however they both showed that tribbles expression alone is not enough to stop
mitosis. Other studies went further and provided a molecular model for Tribbles function,
demonstrating that slbo levels, a fly homologue of mammalian CCAAT/enhancer-binding
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protein (CEBP) transcription factor, are regulated by Tribbles in a ubiquitin-dependent
manner and that Tribbles has a regulatory role during oogenesis, affecting fly wing
development [91]. Overall, Tribbles was shown to regulate embryonic development in
Drosophila at several stages through its regulation of Cebp and Cdc25 protein levels by
mediating their degradation.

Mammalian TRIB Family of Proteins Structure, Homology and Functions
Since Tribbles discovery in Drosophila, 3 mammalian homologs have been identified,
named TRIB1, 2 and 3. The human genes share high degrees of sequence similarity with
each other, with TRIB1/TRIB2 sharing 71.3%; TRIB2/TRIB3 sharing 53.7%; and
TRIB1/TRIB3 sharing 53.3% of similarity [92]. Also, the TRIB family of proteins have been
shown to be highly conserved among human and mouse, with sequence similarities of
97.5% for TRIB1, 99.2% for TRIB2 and 81.2% [93]. for TRIB3. Despite being so highly
conserved, each TRIB protein has been demonstrated to have different functional
properties.
The TRIB family of proteins are ubiquitously expressed, and their structure is comprised
of three regions: a N-terminal region, a central pseudokinase domain and a C-terminal
region [92, 94]. The N-terminal region is a short, 60–80-amino acid region which highly
enriched in proline and serine, named a PEST region, which is known to be present in
proteins with short half-lives [95]. The central pseudokinase domain of the TRIB family is
similar to a canonical kinase, however it lacks critical motifs and residues that are
necessary for anchoring ATP and phosphate transfer, as well residues important for the
catalysis and orientation of ATP, which makes them catalytically inactive [96, 97]. Even
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though they do not have catalytic activity, pseudokinases have been proved vital in the
regulation of many cellular processes and have been associated with key biological
pathways dysregulated in disease. The C-terminal region of TRIB proteins contains two
motifs: a constitutive photomorphogenic 1 (COP1) ubiquitin ligase binding motif and a
MEK1 (MAPK (mitogen-activated protein kinase)/ERK (extracellular- signal-regulated
kinase) kinase 1)-binding motif, both of which are highly conserved in mammalian TRIB
homologues [98]. Both MEK1 and COP1 binding sites result in TRIB modulation of the
MAPK/ERK signal transduction pathway via increased ERK phosphorylation, and
proteasomal degradation of target protein by interaction with the COP1 E3 ubiquitin ligase,
which is facilitated by the pseudokinase domain which anchors target proteins near the
E3 ligase [99, 100]. This mechanism helps facilitate TRIB family pseudokinases best
known function, which is COP1‐dependent degradation of the transcription factors CEBPs
[101-104].
CEBP proteins (CEBP α, β, γ, δ, ε, ζ), are members of the basic-leucine zipper class of
transcription factors that act as homo or heterodimers [105]. TRIB protein family members
have been broadly associated to interact and regulate the CEBP transcription factors,
which has been shown to affect cell development and differentiation in different systems
[101, 106-108]. CEBPs is an intron-less gene that is transcribed into a single mRNA, which
is translated into two isoforms by alternative start codon usage; the full-length CEBPa
(p42) and a shorter CEBPa (p30), which that lacks the full trans-activation potential of p42,
which is crucial for cell differentiation [109, 110]. The ratio between the p30 and the p42in
cells is critical for the development of granulocytes, as the p30 protein fails to induce
differentiation and increases cell proliferation of myeloid progenitors [111].
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TRIB family members have been associated with the development or protection of certain
cancers. In the hematopoietic system, TRIB1 and TRIB2 mediate degradation of the
CEBPα p42, which results in an excess of the p30 isoform and impaired neutrophil
differentiation and enhanced eosinophils, monocytes and macrophages differentiation in
a mechanism that is similar to what occurs in acute myeloid leukemia (AML) patients with
CEBPA mutations [112, 113]. TRIB1 is a biomarker of immune mediated chronic allograft
failure associated with a poor prognosis in the setting of kidney disease transplantation
[114]. TRIB2 was highlighted as a potential predictive biomarker for treatment response
in blood cancer patients because it confers sensitivity to the novel treatment agent
Venetoclax [115].
In addition to control of hematopoietic cell development, TRIB proteins have also been
shown to be involved in the regulation of innate inflammation signaling, endoplasmic
reticulum stress and adipocyte differentiation; this through protein interactions with NF‐kB,
ATF4 and AKT, respectively [103, 116, 117]. Additional to cancer pathologies, links
between the dysregulation of TRIB family of proteins and other diseases and traits have
been described. Changes in expression TRIB3 have been associated with progression of
Parkinson’s disease as well as changes on inflammatory gene expression in diabetic
kidney disease [118, 119]. Also, as mentioned before, multiple unbiased GWAS studies
have indicated multiple associations between TRIB1, plasma lipid traits, and the
development of CAD [120].
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Mammalian TRIB1, a GWAS hit for multiple cardiometabolic traits
The focus of this dissertation is characterizing TRIB1, a genetic locus identified in multiple
GWAS with multiple metabolic phenotypes. The locus 8q25, which contains the TRIB1
gene, was first shown to be involved in plasma lipid metabolism by two papers that showed
noncoding variants within in the TRIB1 gene locus are associated with circulating
triglyceride and LDL-C levels in humans [79, 80]. The GLGC then published metaanalyses comparing more than 190,000 individuals of diverse genetic background that
further validated the relationship of TRIB1 with lipid metabolism [69, 86]. The findings of
these studies displayed TRIB1 as the only novel locus from these studies to be associated
with all 4 lipid traits (triglycerides, total cholesterol, HDL-C and LDL-C) as well as CAD.
Further, it was the first time that TRIB1 had been associated with the regulation of lipid
metabolism, creating a lot of interest in determining the mechanisms contributing to these
traits. Since its original GWAS discovery, many other studies have corroborated the
importance of TRIB1 in the regulation of plasma lipids. More recently in the Million Veteran
Program GWAS of lipids in more 300,000 participants, the lead variant rs2001846 near
TRIB1 was associated with a significant increase in LDL-C (p = 2.73E-82) [81]. Additional
GWAS studies have also associated variants within the TRIB1 locus with the development
of hepatic steatosis [121, 122], adiponectin levels [123] and levels of liver enzymes such
as alanine transaminases (ALTs) [124], making this gene even more interesting to study.
The significantly associated SNPs in this locus fall around 40 kb upstream of the TRIB1
gene, and it was annotated as the gene of interest due to its position as the nearest gene
to the lead SNP. However, no direct expression quantitative trait loci (eQTLs) have yet
been identified for TRIB1, which mean that no changes in TRIB1 expression have been
directly associated with the specific traits associated within this locus. Even though no
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eQTLs have been found in humans, many studies have demonstrated the important role
of TRIB1 in the regulation of plasma lipids and other traits using cell and animal models
and I will be discussing these finding in the next section.
Hepatic TRIB1 in the regulation of plasma lipids metabolism
Since the TRIB1 GWAS lipid associations were indicated, a lot of interest developed in
determining how TRIB1 affects plasma lipids and CAD. Using a model of AAV-mediated
overexpression of Trib1 in adult C57B/6 mice, Burkhardt et al. [125] demonstrated that
increasing levels of hepatic Trib1 decreased plasma total cholesterol, HDL-C, LDL-C, and
triglycerides levels in a dose-dependent manner. Mice overexpressing Trib1 also showed
a decrease in triglyceride production and hepatic lipogenic gene expression. The authors
repeated the Trib1 overexpression in various mouse models of lipid metabolism, including
the Ldlr KO hyperlipidemic model and the Ldlr KO /Apobec1 KO/human apoB transgenic
(LAhB) humanized mouse model, which have lipid profiles similar to humans. In all mouse
models tested, Trib1 overexpression resulted in significant reductions in plasma
cholesterol and triglycerides. In the LAhB mice, Trib1 overexpression also caused a
significant reduction in plasma apoB protein. The authors also performed in vitro studies
with Hepg2 cells and ex vivo studies of primary hepatocytes and showed that these cells
have reduced cellular triglyceride production and secretion, with HepG2 cells
overexpressing TRIB1 also showing a reduction in apoB protein. Furthermore, using a
previously reported whole-body deletion model of Trib1 on a mixed background, the
investigators demonstrated that deletion of Trib1 leads to increased plasma total
cholesterol, VLDL, LDL, triglyceride secretion and hepatic lipogenesis. Based on their
results, they concluded that TRIB1 can modulate VLDL secretion from the liver by
regulating the level of triglycerides available for VLDL assembly in hepatocytes [125].
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In another publication, Bauer et al. [104] demonstrated that hepatic specific deletion
of Trib1 increases hepatic triglyceride content, lipogenic gene expression, and de novo
lipogenesis in mice. These mice also had increased hepatic CEBPa protein, which was
shown to be both necessary and sufficient to drive the hepatic lipogenic phenotypes in
Trib1 hepatic deleted mice [104]. The results from these studies established that
TRIB1 regulation of hepatic lipogenesis is mediated through CEBPa. Additionally, Trib1
liver knockout mice had increased plasma lipids; however, the association of CEBPa
regulation with this phenotype was not fully elucidated [104].
CEBPa is well known for its function as a regulator of myeloid cell development and
hematopoiesis [126], however it is also known to be involved in the regulation of energy
homeostasis [127]. CEBPa protein is highly expressed in adipose tissue and the liver in
mouse and humans, and has been broadly described as regulator of adipogenesis, critical
for glucose and lipid homeostasis and for the regulation of several metabolic genes in the
liver [104, 128, 129]. CEBPa whole body knockout neonates have been reported to die
postnatally due to lack of glycogen, severe hypoglycemia, and lack of lipid accumulation
in their hepatocytes and adipocytes [127]. These results confirmed the importance of
CEBPa for energy homeostasis, glucose metabolism and postnatal survival in mice.
CEBPa has also been implicated the regulation of hepatic lipogenesis in mouse models
of obesity. Hepatic deficiency of CEBPa in the leptin-deficient ob/ob mouse model of
obesity and db/db mouse model of diabetes abrogated fatty liver caused by a high
carbohydrate diet, decreased circulating triglycerides, lipogenic gene expression and the
transcription of SREBP1 [130, 131]. These reports support a role for CEBPa in the
regulation of lipid metabolism and go in line with the results from Bauer et al., [104] which
elucidated the roles of Trib1 and CEBPa in hepatic lipid metabolism.
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Additional to CEBPa, other hepatic mechanisms have been proposed by which TRIB1
regulates plasma lipids, although not fully explored. As mentioned before, The C-terminal
region of TRIB proteins contain a MEK1 binding motif which has been shown to modulate
MAP kinase signaling by promoting the phosphorylation of ERK1/2 [99]. Phosphorylation
of ERK1/2 has previously been shown to down-regulate the expression of Stearoyl-CoA
desaturase-1 (SCD1) in HepG2 cells, which encodes a protein (SCD1) that that catalyzes
a rate-limiting step in the synthesis of unsaturated fatty acids [132]. Scd1 has consistently
been shown to be differentially expresses in mouse models of Trib1 overexpression and
hepatic deletion [104, 125]. Inhibition of MEK/ERK signaling using an ERK1/2 inhibitor
was also shown to improve VLDL assembly in HepG2 cells and to increase apoB secretion
from these cells [133]. These observations are in line with the observed lipid phenotypes
of mice with hepatic overexpression and hepatic deletion of Trib1, thus implicating altered
MAP kinase signaling as a potential mechanism of metabolic regulation by TRIB1.
However, these findings have not been replicated on in vivo models of TRIB1 metabolism
and more research is needed to fully elucidate this mechanism.
TRIB1 has been reported to regulate hepatic lipogenesis via the carbohydrate response
element binding protein (ChREBP) [134]. In vitro overexpression and mammalian yeast
2-hybrid assays showed that TRIB1 interacts and regulates both the mRNA and the
protein levels with the transcription factor ChREBP, this by promoting its ubiquitination
and proteasomal degradation in a process similar to TRIB1 and CEBPa relationship [134].
ChREBP is a glucose sensing transcription factor that is involved in the regulation of genes
associated with hepatic lipogenesis [135]. Some of ChREBP targets are pyruvate kinase,
liver and RBC (PKLR), Acetyl-CoA Carboxylase Alpha (ACACA), Fatty Acid Synthase
(FASN) and ChREBP itself [135], some of which are differentially expressed in mouse
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models of Trib1 overexpression or down-regulation [104, 125]. These findings support the
notion that TRIB1 modulates ChREBP control of lipogenesis.

Another study also used a yeast-two-hybrid screen and found the Sin3A-associated
protein of 18 kDa (SAP18) to be a novel binding partner of TRIB1, which demonstrated
that knockdown of Sap18 in mouse liver decreased plasma lipid and increased hepatic
lipid levels, while Sap18 overexpression had the opposite effects [136]. They also
performed transcriptome analysis of the mouse liver revealed that changes in Sap18
expression inversely regulated MTP levels, which is crucial for the assembly of VLDL
particles. ChIP analysis showed that SAP18, TRIB1 and mSin3A bind together at the
regulatory sequences of the MTP, an interaction that its crucial for MTP regulation [136].
The findings further support TRIB1 involvement in the regulation of plasma and hepatic
lipids. In support of this findings suggesting a possible effect of TRIB1 on MTP, another
group showed that knockdown of TRIB1 in primary human hepatocytes leads to MTP
mRNA and protein reduction, however, this was attributed to reduced levels of hepatocyte
nuclear factor 4 alpha (HNF4a), a highly conserved member of the nuclear receptor family
[137]. HNF4a is essential for triglycerides and cholesterol homeostasis and bile acid
metabolism, and it also helps regulate the expression of several key lipoprotein regulators
including APOC3 and MTP [138]. In several in vitro and ex vivo cell lines, TRIB1
suppression resulted in decreased while TRIB1 abundance increased HNF4A and they
also demonstrated that TRIB1 and HNF4A can form complexes in vivo [137]. The data
presented in these last studies propose a model where TRIB1 regulates MTP activity
through its interaction with SAP18 and HNF4a. However, the results from these studies
propose an opposite directionality of triglyceride levels as to what has been observed in
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mouse models of Trib1 overexpression and knockout, which suggest these interactions
need to be fully explored using in vivo models.

Overall, there are numerous possible physiological and molecular mechanisms by which
hepatic TRIB1 regulates plasma lipid metabolism that remain unclear. Most of the
established mechanistic partners of TRIB1 had been studied using in vitro models, which
need to be investigated and confirmed in in vivo models. Further, the molecular and
physiological mechanisms by which TRIB1-CEBPa interactions affect plasma lipids
remains to be elucidated.

Goal of this Thesis

The main goal of this dissertation is to functionally characterize TRIB1, a gene associated
with multiple cardiometabolic traits. My first aim is to determine the physiological
mechanism by which murine hepatic Trib1 deletion increases plasma lipids. I will explore
how murine hepatic Trib1 deletion affects the processes of liver lipoprotein production,
secretion, and clearance. My second aim is to determine the molecular mechanism by
which Trib1 regulates plasma lipids in mice, with my main target being exploring if Trib1
regulation of CEBPA is involved in the modulation of plasma lipid metabolism. My third
aim is to explore the underlying mechanism of the highly penetrant neonatal lethality we
observed in whole body Trib1 knockout mice. Overall, the findings from my studies will
expand the knowledge as to how murine Trib1 regulates multiple cardiometabolic traits,
which will shed light into similar mechanisms in humans.
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CHAPTER 2: METHODS
Animals
Mice harboring a conditional allele of Trib1 (C57BL/6-Trib1tm1.1mrl/ Trib1flox;flox) were
provided by Merck and were produced for Merck by contract with Taconic; details of the
mice can be found at http://www.taconic.com/10265. Trib1 constitutive knockout mice
(C57BL/6-Trib1tm1.2mrl/ Trib1 KO) were provided by Merck and were produced for Merck
by

contract

with

Taconic;

details

of

the

mice

can

be

found

at

https://www.taconic.com/10385. Previously reported mice harboring a conditional allele of
Cebpa (Cebpatm1Dgt/J / Cebpaflox;flox) were obtained from the Jackson Laboratory (stock
number 006447). C57BL/6J wild type mice (Controls) were obtained by the Jackson
Laboratory (000664). Ldlr constitutive knockout (Ldlr KO) mice were obtained from
Jackson Laboratory (stock Number 002207). All mice were maintained in a monitored
small animal facility at the University of Pennsylvania under Institutional Animal Care and
Use Committee -approved protocols. Mice were fed ad libitum with a standard chow or
Western type diet (WTD) containing 40% kCal fat, 43% kCal carbohydrate and 17% kCal,
protein from OpenSource Diets (D12079B, Research Diets) for the indicated periods of
time. For experiments with WTD, mice were injected with adeno-associated virus (AAV),
then plasma lipids were monitored for 5 weeks under chow feeding before switching to
WTD. All mice were provided ad libitum access to water and were maintained on a 12/12
light cycle with lights off from 7:00 p.m. to 7:00 a.m. daily. For all studies, male mice aged
10–12 weeks were used; for some of the studies, female mice of similar age were also
included. Five to ten mice per group were used for all studies.
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Adeno-Associated Virus 8 (AAV-8) Viral Vector Preparation
AAV serotype 8 vectors containing an empty vector expression cassette (AAV8-Null) or
encoding Cre recombinase (AAV8-CRE) were generated by the University of
Pennsylvania Vector Core (Philadelphia, Pennsylvania, USA). The transgene in these
vectors is selectively expressed in hepatocytes driven by the thyroxine-binding globulin
(TBG/Serpina7) promoter [139]. For all experiments utilizing AAV-CRE or AAV-NULL,
animals were injected with AAV vectors at a dose of 1.5 × 1011 genome copies via i.p.
injection and examined at the indicated time points. Control mice refer to either Trib1fl/fl
mice receiving AAV-NULL or wild type mice receiving AAV-CRE. Trib1Δhep mice refer to
Trib1fl/fl mice receiving AAV-CRE. CebpaΔhep mice refer to Cebpafl/fl mice receiving AAVCRE. Trib1Δhep; CebpaΔhep also named double knockout mice (DKO) refer to our crossed
line between Trib1fl/fl and Cebpafl/fl mice receiving AAV-CRE.
Atf3 and Luciferase Control siRNA injections
Atf3 and luciferase control siRNA were provided by Alnylam. Control and Trib1Δhep mice
were injected with Atf3 or luciferase control siRNA at a dose of 10mg/kg and examined at
the stated time points.
Plasma lipid phenotypic characterization
Blood samples were collected from mice after isoflurane anesthesia by retro-orbital
bleeding using EDTA-coated glass tubes. Blood was centrifuged at 10,000 rpm for 7 min
at 4°C and plasma was obtained. Plasma total cholesterol, HDL-C, triglyceride,
phospholipids and ALTs levels were measured using an Axcel clinical autoanalyzer (Alfa
Wassermann Diagnostic Technologies). Non-HDL-C was calculated as the difference
between the TC and HDL-C measurements. All measurements were made from 4 hour24

fasted plasma samples unless stated otherwise. In addition, plasma samples were pooled
by experimental group after collection and 150 μl of plasma was separated by Fast Protein
Liquid Chromatography (FPLC) on a Superose 6 gel-filtration column (GE Healthcare Life
Sciences) into 0.5 ml fractions. Total cholesterol and triglycerides were measured from
FPLC-separated fractions using Infinity Liquid Stable cholesterol and triglyceride reagents
(Thermo Scientific) in 96-well microplates with a Synergy Multi-Mode Microplate Reader
(BioTek).
Hepatic Lipid characterization
Hepatic triglycerides and total cholesterol were measured from animals sacrificed by
isofluorane inhalation and cervical dislocation, flash frozen in liquid nitrogen and stored at
-80°C until processed. Frozen liver (~100mg) were weighed and homogenized in 1xPBS.
Liver homogenates were diluted (1:10-1:20 dilutions) and then incubated with 1%
deoxycholate (Acros Organics, Inc) for triglycerides and 0.25% deoxycholate for total
cholesterol. Total cholesterol and triglycerides were measured using Infinity Liquid Stable
cholesterol and triglyceride reagents (Thermo Scientific) for colorimetric assays.
Plasma Glucose characterization
Blood glucose, lactate and ketone bodies were measured using a One-Touch Ultra
glucometer (Lifescan, Inc.), Lactate Plus lactate meter (Nova Biomedical) and Nova Max
Plus Ketone meter respectively at indicated nutritional conditions.
Measurement of Tissue Glycogen Levels
Neonatal mice at postnatal day 1 were sacrificed by decapitation and liver tissue was flash
frozen in liquid nitrogen. Frozen tissue samples (~10µg) were homogenized in PBS.
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Homogenates were quantified for protein by the BCA method (Thermo Scientific). Tissue
samples were used for detection of glycogen levels by colorimetric assay protocol
according to manufacturer’s instructions (Biovision). Glycogen levels in samples were
determined from a standard-curve method generated by the assay.
Oral fat tolerance test
Mice were fasted overnight 12-16 hours, then bled for baseline triglycerides levels. The
mice were then gavaged with olive oil (20ul x BW (g).) and plasma was collected at 1, 3,
5 and 7 hours post-gavage. Triglyceride levels were measured using Infinity Liquid Stable
triglyceride reagents (Thermo Scientific) in 96-well microplates with a Synergy Multi-Mode
Microplate Reader (BioTek). Data was plotted as the change from baseline from for every
timepoint and the resulting data was analyzed calculating the area under the curve.
Glucose tolerance test
Mice were fasted overnight for 14-16 hours. Mice were then injected with 10ul x BW (g) of
glucose from a 20% w/v glucose solution, via intraperitoneal (I.P.) injection. Blood was
collected by tail bleeding and was used to measure glucose concentrations using a OneTouch Ultra glucometer (Lifescan, Inc.) at 0, 15, 30, 60, 90 and 120 minutes after glucose
administration.
Insulin tolerance test
Mice were fasted for 6 hours before I.P. injection of 0.75U/kg body weight of recombinant
insulin (Novolin R; Novo Novodisk A/S). Blood glucose concentrations were measured
using a One-Touch Ultra glucometer (Lifescan, Inc.) at 0, 15, 30, 60, 90 and 120 minutes
after insulin administration.
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LDL-ApoB Kinetic Experiments
LDL was isolated from human plasma by ultracentrifugation. LDL ApoB was iodinated with
125

I directly using the iodine mono-chloride method [140]. Approximately 2.0 ml of LDL in

10 mM ammonium bicarbonate buffer (0.2–0.4 mg/ml) was iodinated with 1 mCi of 125I
(PerkinElmer), 300 μl of 1 M glycine, and 150 μl of 1.84 M NaCl/2.84 μM ICl solution,
vortexed, and applied to a PG-10 desalting column (Amersham Biosciences) that was preequilibrated with 0.15 M NaCl/1 mM EDTA solution. Iodinated proteins were eluted in a
final volume of 2.5 ml in NaCl/EDTA solution and dialyzed against PBS before
measurement of protein concentration by BCA assay,

125

I activity was confirmed by

gamma counting and fractionated by FPLC to measure cholesterol and 125I activity in the
LDL fractions. For

125

I-LDL-ApoB clearance studies, iodinated LDL-ApoB specific activity

was approximately 50-100 counts/ng protein. Mice were administered by intravenous tail
vein injection with approximately 2 million counts

125

I-LDL in 100µl of plasma. Mice were

bled 2 minutes after injection, then again at 1 , 2 , 3 , 4 , 6 , 12 , and 24 hours after
radioisotope administration and sacrificed at 24 h.

125

I activity at each timepoint was

measured from 5 μl of each plasma sample by counting on a Packard Cobra II AutoGamma counter. The relative activity at each time point was determined as the fraction of
activity at 2 min for each mouse respectively.
VLDL-ApoB Kinetic Experiments
VLDL was isolated from human plasma by ultracentrifugation. VLDL ApoB was iodinated
with 125I directly using the iodine mono-chloride method using the same method described
for LDL iodination [140]. Mice were bled at 1 min, 5 min, 15min, 30min, 1h, 3h, 6 h, and
24 h after radioisotope administration and sacrificed at 24 h. 125I activity at each timepoint
was measured from 5 μl of each plasma sample by counting on a Packard Cobra II Auto27

Gamma counter. To get VLDL-ApoB specific counts, plasma was subjected to isopropanol
precipitation and the precipitate was measured for counts on the gamma counter. The
relative activity at each time point was determined as the fraction of activity at 1 min for
each mouse, respectively.
Triglyceride and apoB secretion Experiments
Mice were fasted for 4 hours and then injected intravenously with 0.67mg/g body weight
Pluronic F127 NF Prill Poloxamer 407 (P407) (BASF, material 30085239) and 300-400µCi
35

Easytag EXPRES

S protein labeling mix (35SMet/Cys) (Perkin Elmer NEG772). Blood

samples were taken immediately prior to the P407/35S Met/Cys injection and at 30, 60, 90,
and 120 minutes post injection. Blood samples were kept on ice and centrifuged to collect
plasma within 15 minutes of collection. Plasma triglycerides concentration was measured
at all time points by colorimetric assay with the Infinity Liquid Stable triglyceride reagents
(Thermo Scientific).
Newly synthesized and total secreted total plasma apoB100 was measured by the
incorporation of 35S Met/Cys into apoB100 that was secreted into the systemic circulation
during the 2 hour experimental period. Total plasma was boiled in Laemli sample buffer
and separated on a 3-8% Tris Acetate gel (Novex), the gel was dried onto filter paper
under vacuum, and the labeled proteins visualized by autoradiography. The apoB100
bands were cut and analyzed for

35

S activity by liquid scintillation counting. To mitigate

differences in total labeled hepatic protein synthesis, counts were adjusted based on the
incorporation of

35

S methionine into all proteins in plasma trichloroacetic acid (TCA)

precipitated protein counts. To determine TCA precipitated protein counts, 5µl of plasma
was blotted onto a 1x1cm square of filter paper. Plasma proteins were precipitated by
incubating the filter paper in 20% TCA on ice followed by 10% TCA heated to 100˚C. The
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filter paper was subsequently rinsed with 100% ethanol, dried, and

35

S activity calculated

by liquid scintillation counter.
Sucrose Gradient Ultracentrifugation Experiment
Sucrose gradient ultracentrifugation of apoB-containing lipoproteins was conducted as
previously described [141]. All solutions contained 0.1 mM leupeptin, 1 μM pepstatin A,
0.86 mM phenylmethylsulfonyl fluoride, 100 units/ml aprotinin, 5 μM ALLN, 5 μM EDTA,
150 mMNaCl, and 50 mM phosphate-buffered saline, pH 7.4. The sample layer was
prepared by diluting 200µl of pooled plasma from the 120 min post-injection time point
from mice in the apoB secretion studies in 2.3 ml of PBS and adding 2.5 ml of 25% sucrose
in PBS. The sucrose gradient was formed by layering from the bottom of the tube: 2 ml of
47% sucrose, 2 ml of 25% sucrose, 5 ml of sample in 12.5% sucrose, and 3 ml of
phosphate-buffered saline. The gradients were spun at 35,000 rpm in a Beckman SW41
rotor for 65 h at 12 °C, and then 12 fractions were removed from the top to the bottom and
subjected to immunoprecipitation for apoB.
Western blot analysis
Protein extracts were prepared from ~100mg of liver tissue homogenized in Lysis Buffer
(25mM Tris-HCL, 10mM Na4P2O7, 1% NP40, 10mM NaF, 1mM EGTA, 1mM EDTA, 1mM
PMSF, 5ug/ul Leupeptin, 5ug/ul 10nM okadaic acid, Protease Inhibitor tablet (Roche),
Phospho tablet (Roche)). Samples were homogenized, shaken for an hour at 4 degrees
and centrifuged at 12,000g for 10 min. Protein was separated by SDS-PAGE using the
NuPage system (Invitrogen). ApoB Antibody was acquired from Abcam (ab31992), LDLR
antibody was acquired from Abcam (ab52818), monoclonal anti B-Actin antibody- clone
AC-15 was acquired from Sigma Aldrich (A5441), CEBPα antibody was obtained from Cell
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Signaling (D56F10) and pEIF2a was obtained from Enzo Life Sciences (BML-SA405). For
ATF3, SREBP1 and SREBP2 a nuclear enriched isolation protocol was used. Protein
extracts were prepared from ~100mg of liver tissue homogenized in Lysis Buffer (50mM
HEPES, 10mM Na4P2O7, 1% NP40, 300mM NaCl, 0.2mM EGTA, 10mM EDTA, 1mM
MgCl2, 1mM CaCl2, 1mM PMSF, 5ug/ul Leupeptin, 5ug/ul 10nM okadaic acid, Protease
Inhibitor tablet (Roche) and 20% glycerol. Samples were homogenized, shaken for an
hour at 4 degrees, centrifuged at 15,000g for 30 min and then the supernatant was
sonicated. Protein was separated by SDS-PAGE using the NuPage system (Invitrogen).
ATF3 antibody was obtained from Novus Biologicals (NBP1-85816), SREBP1 antibody
(2A4- SC 13551) and SREBP2 antibody (NB100-74543). ECL HRP-conjugated secondary
antibodies were from GE Healthcare Life Sciences and the Crescendo ECL reagent
(Millipore) was used for protein development.
Albumin protein levels
Circulating Albumin levels were determined in plasma collected after 4-hour fasting using
the Mouse Albumin ELISA Kit, E99-134 according to manufacturer’s instructions (Bethyl
Laboratories).
RNA Isolation and Quantitative RT-PCR
RNA was collected from approximately 100 mg flash-frozen liver tissue using the mirVana
Kit (Invitrogen) following the manufacturer’s protocol. cDNA was produced from 1 μg of
total RNA with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems)
following the manufacturer’s instructions. Quantitative reverse transcription PCR (qRTPCR) analysis was performed using standard TaqMan Gene Expression probes
(Invitrogen) on a QuantStudio RT-PCR machine. The relative quantity of each mRNA was
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calculated using the ΔΔCt method and normalized to the combined mean Ct of Mrlp19,
Ywhaz, and Ipo8 housekeeping genes. Table 1 contains the sequences for all probes
used for qRT-PCR.
Statistics
All data are reported as the mean ± SEM. Statistical comparisons between groups were
performed using a two-tailed Student's t-test, one-way ANOVA, or two-way ANOVA as
appropriate and when assumptions of distribution of the data were valid. Statistical
significance was defined as p < 0.05.
Gene-expression profiling (RNA Seq) and Ingenuity Pathway Analysis
RNA was collected from approximately 100 mg flash-frozen liver tissue using the mirVana
Kit (Invitrogen) following the manufacturer’s protocol. Total RNA was analyzed using the
Agilent RNA 600 Nano Kit following the manufacturer’s protocol. Whole Transcriptome,
High-throughput library was prepared using Illumina truSeq stranded mRNA kit.
Sequencing was performed on a HiSeq4000 (100 bp, single end reads), to get
approximately 312 million reads. RNA-Seq and data analysis were performed by the Penn
Functional Genomics Core (Philadelphia, Pennsylvania, USA). Raw sequence files (fastq)
for 27 samples were mapped to the transcriptome using Salmon [142] against the mouse
transcripts described in genecode (version M22, built on the mouse genome GRCm38.p6)
[143]. Transcript counts were summarized to the gene level using tximport [144], and
normalized and tested for differential expression using DESeq2 [145]. Differential
expression was determined using a False Discovery Rate cutoff of 10%.
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Mass spectrometry analysis
Samples were prepared and ran as described in the Western blot methods section. Gels
were stained with Coomassie blue staining, and the bands of interest were submitted for
analysis at the Quantitative Proteomics Resource Core at the School of Medicine at the
University of Pennsylvania. Peptides were analyzed on a an Orbitrap Fusion (Thermo
Scientific) attached to an UltiMate™ 3000 RSLCnano System (Thermo Scientific) at 400
nL/min. Proteome Discoverer (Thermo Fisher Scientific, version 2.3) was used to process
the raw spectra. The uniprot Mus musculus database was used for database searching.
For label-free quantitation, All the chromatographic data were aligned and normalized
the peptide groups and protein abundances, impute missing values and scale them. Here,
it was applied the normalization of the total abundance values for each channel across all
files, equalizing the total abundance between different runs.
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Table 1. TaqMan Probes used for Gene Expression Analysis by qRT-PCR

Gene Symbol

TaqMan Code

Trib1

Mm00454875_m1

Cebpa

Mm00514283_s1

Ldlr

Mm01177349_m1

Atf3

Mm01177349_m1

Srebpf1

Mm00550338_m1

Srebpf2

Mm01306292_m1

Fasn

Mm00662319_m1

Acaca

Mm01304257_m1

Pepck

Mm01247058_m1

G6pc

Mm00839363_m1

Gys1

Mm01962575_s1
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CHAPTER 3:
Trib1 regulates plasma lipids by modulating both the rates of hepatic lipoprotein
secretion and LDLR-mediated clearance

ABSTRACT

Genetic variants near the TRIB1 gene are significantly associated with plasma lipid traits
and coronary artery disease. While data suggest TRIB1 is the causal gene for these traits,
the physiological mechanisms by which its protein product TRIB1 affects plasma lipids are
not fully understood. Plasma lipid levels are directly impacted by the rates of secretion
from the liver and intestines in the form of triglyceride rich lipoproteins (VLDL and
chylomicrons), as well as by the rates of plasma clearance by either LPL-mediated
triglyceride hydrolysis or LDLR-mediated clearance by the liver. In these studies, I sought
to elucidate how TRIB1 affects plasma lipids by investigating each of these possible
mechanisms. Using a Trib1 hepatocyte specific deletion mouse model (Trib1Δhep), I
demonstrated that Trib1Δhep mice have significantly increased plasma total cholesterol,
HDL cholesterol, non-HDL cholesterol, LDL cholesterol and apoB protein levels, as well
as impaired postprandial triglyceride clearance. I also showed that Trib1Δhep mice have
markedly delayed catabolism of LDL-apoB and VLDL-apoB due to significantly decreased
Ldlr mRNA and protein expression. In the absence of the Ldlr, deletion of Trib1 did not
further impair LDL-apoB or VLDL-apoB catabolism, suggesting that the apoB clearance
phenotypes are due to the Trib1-mediated decrease in Ldlr. I also demonstrated that
Trib1Δhep mice have increased secretion of apoB containing lipoproteins, which was
replicated in the absence of Ldlr. These findings establish hepatic Trib1 as a critical
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regulator of multiple metabolic pathways affecting plasma lipids, and as a novel regulator
of the LDLR.

INTRODUCTION

The TRIB1 gene, which encodes Tribbles homolog 1 protein (TRIB1), has been suggested
as the causal gene for the highly robust GWAS signals at human chromosomal locus 8q24
for a remarkable number of cardiometabolic traits, including plasma lipids and lipoproteins,
hepatic steatosis, adiponectin levels, and coronary artery disease [69, 79, 124, 146]. The
tribbles gene was first identified in Drosophila as a regulator of cell division and
morphogenesis and was shown to regulate the proteins encoded by string and slbo, the
Drosophila homologs of the dual phosphatase CDC25A, and CEBPa respectively [88, 89,
91]. In humans, TRIB1 encodes a highly conserved pseudokinase that functions as a
signal transduction pathway modulator and scaffolding protein, including interacting with
the E3 ubiquitin ligase COP1 to target the transcription factors CEBPa and CEBPb for
ubiquitination and proteasomal degradation, a process that has been broadly explored in
myeloid cell differentiation [100].
Since the establishment of a genetic link between TRIB1 and cardiometabolic traits,
limited investigation of its role in the liver has been performed. Our laboratory previously
reported that Trib1 overexpression in mouse liver decreased plasma lipids, hepatic de
novo lipogenesis, and very low-density lipoprotein (VLDL) production [125]. We also
demonstrated that Trib1 hepatic deletion in mice increases plasma lipids, hepatic fat and
de novo lipogenesis [104]. Furthermore, Trib1 deletion significantly increased hepatic
levels of CEBPa protein, which helped explain the increased de novo lipogenesis and
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hepatic lipid phenotypes [104]. However, questions regarding the physiological
mechanism by which TRIB1 specifically regulates plasma lipids and LDL-C metabolism
remained unanswered.
Even though TRIB1 is ubiquitously expressed, in these studies I focused in understanding
how hepatic Trib1 regulates plasma lipid metabolism in mice. The liver is one of the most
important tissues for lipid homeostasis, and therefore understanding the effects of hepatic
Trib1 expression is critical to elucidate its role in lipid metabolism. Further, constitutive
Trib1 deletion on a C57BL/6 background presents a highly penetrant neonatal lethality
(discussed in chapter 5). In this chapter, I functionally characterize a Trib1 hepatocyte
knockout (Trib1Δhep) mouse model and determine the effects on multiple pathways that
regulate plasma lipids. I demonstrated that in addition to the previously reported Trib1
effects on hepatic lipogenesis, VLDL secretion and lipid levels, hepatic Trib1 is involved
in the regulation of post prandial triglycerides clearance, the catabolism of VLDL and LDL
apoB lipoprotein particles through its regulation of LDLR, and the secretion of small apoB
particles form the liver. Our findings establish hepatic Trib1 as a player of multiple
physiological pathways that regulate plasma lipid metabolism as well as a novel regulator
of the LDLR.

RESULTS

Generation of hepatocyte-specific Trib1 knockout mouse line (Trib1Δhep)
To assess the effects of hepatic Trib1 deletion on plasma lipids, we acquired C57BL/6
mice with loxP sites flanking the second exon of Trib1 (Trib1flox/flox). Mice were
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administered AAV-Cre to induce Trib1 hepatocyte-specific deletion. The results from these
mice were compared to control mice, which were wild type C57BL/6 mice receiving an
AAV-CRE injection. Male Trib1Δhep mice had greater than 95% reduction in liver Trib1
mRNA expression eight weeks after AAV-CRE injection (Figure 3.1A). Mice were fed a
western type diet (WTD) for 22 weeks to represent the caloric intake of the typical North
America diet. Male Trib1Δhep mice on WTD similarly had a significant reduction in hepatic
Trib1 mRNA expression (Figure 3.1B). Female mice also showed >95% percent deletion
in Trib1 mRNA expression at similar time-points both on chow and WTD (Figure 3.1C, D).
The residual expression of Trib1 is likely attributable to its expression in other cells in the
liver. These results demonstrate efficient and stable hepatocyte Trib1 deletion using our
approach.

Trib1Δhep mice have increased plasma lipids and apoB protein levels.
We then went on to confirm hepatic Trib1 effects on plasma lipids. Male Trib1Δhep mice
had no change in triglyceride levels (Figure 3.2A) but had significantly increased total
cholesterol (Figure 3.2B), HDL-C (Figure 3.2C) and non-HDL-C levels (Figure 3.2D),
measured four weeks post-deletion in chow diet. After challenge with WTD feeding, male
Trib1Δhep mice still had no difference in triglyceride levels compared with WT controls
(Figure 3.2E), whereas the differences in total cholesterol (Figure 3.2F), HDL-C (Figure
3.2G) and non-HDL-C (Figure 3.2H) were substantially enhanced over time. Trib1Δhep
female mice had a similar, but more modest plasma lipid phenotype on both chow and
WTD (Figure 3.3). Since apoB is the major lipoprotein component of non-HDL-C, we also
examined plasma for changes in apoB protein abundance and found that Trib1Δhep male
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mice have increased plasma apoB in both chow (Figure 3.4A) and WTD (Figure 3.4B)
conditions.
Trib1Δhep mice have increased LDL triglyceride and cholesterol lipoprotein particles
To determine which specific lipoproteins were increased in the plasma of Trib1Δhep mice,
pooled plasma from mice was fractionated by FPLC. On chow, male Trib1Δhep mice had a
modest increase in triglyceride and total cholesterol in the LDL lipoprotein fractions
compared with control mice (Figure 3.5 A-B). However, after being fed a WTD the
increase of triglyceride and total cholesterol on the LDL lipoprotein fractions was further
amplified in male Trib1Δhep mice (Figure 3.5 C-D). Female Trib1Δhep mice showed a similar
but more modest pattern of increased LDL triglycerides and cholesterol increase on chow
(Figure 3.6 A-B) but had a more robust response after WTD feeding (Figure 3.6 C-D).
These results indicate that Trib1Δhep mice accumulation of plasma lipids is primarily due to
LDL particles, contributing to the increase in total cholesterol and apoB.

Trib1Δhep mice have increased liver lipid accumulation and indications of liver
damage but are resistant to diet induced obesity.
On chow diet, Trib1Δhep male mice had no difference in body weight to control mice (Figure
3.7A). However, after WTD feeding, their body weight was significantly lower than control
mice (Figure 3.7A), even though their plasma lipid levels were significantly increased.
These results suggest that Trib1Δhep mice are resistant to diet induced obesity. Even
though their body weight was not changed or decreased compared to control mice,
Trib1Δhep mice had significantly increased liver to body weight ratio (Figure 73.B), that was
associated with an increased in hepatic triglycerides (Figure 3.7C) and cholesterol (Figure
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3.7D) levels. Trib1Δhep mice also had significantly increased plasma levels of ALTs over
time in chow and WTD (Figure 3.7E), and decreased levels of circulating albumin protein
(Figure 3.7F), both measures that are associated with impaired liver health.

Trib1 LSKO mice have impaired plasma triglyceride clearance.
Although steady state plasma triglycerides did not show significant changes in Trib1Δhep
mice (Figure 3.2 A,E; Figure 3.3A, E), the FPLC results clearly showed that Trib1Δhep mice
accumulate triglycerides in the LDL lipoprotein fractions (Figure 3.5A, C, Figure 3.6A,C).
These results suggest that there might be an impairment in the clearance of plasma
triglycerides in Trib1Δhep mice. To test if plasma triglyceride accumulation is due to its
improper clearance, we performed oral fat tolerance tests (OFTT), which measures the
rates of postprandial lipemia. Upon challenge with an oral fat load, male Trib1Δhep mice,
both on chow and WTD fed conditions, showed significantly impaired TG clearance
compared to control mice (Figure 3.8 A-B), which was confirmed by an increased area
under the curve (Figure 3.8C).

Female Trib1Δhep mice also had a similar defect in

triglyceride clearance on both diets (Figure 3.8D-F). These results indicate that deletion
of Trib1 in hepatocytes markedly impairs the ability of mice to clear triglyceride rich
lipoproteins, thus leading to the increase in plasma triglycerides in FPLC fractions in the
LDL range.
Trib1Δhep mice have impaired LDL and VLDL apoB lipoprotein clearance.
We then tested if the increased cholesterol in the LDL fractions was due to impaired apoB
catabolism. Trib1Δhep and control mice were injected with 125I labeled human LDL and the
decay of plasma

125

I was determined over 24 hours. Male Trib1Δhep mice exhibited
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markedly slower LDL catabolism, both on chow (Figure 3.9 A-B) and on WTD (Figure 3.9
C-D). Similar reductions in LDL catabolism were noted in female Trib1Δhep mice, though
not to the same degree as in male mice (Figure 3.10 A-D). We also examined whether
VLDL-apoB catabolism was delayed. Trib1Δhep and control mice were injected with
VLDL and the decay of plasma

125

I-

I was determined over 24 hours. Trib1Δhep mice had a

125

significant reduction in the rate of VLDL-apoB catabolism compare with control mice
(Figure 3.9 E-F). Thus, Trib1Δhep mice have substantially slower turnover of both LDL-apoB
and VLDL-apoB compared with control mice, both contributing to the accumulation of
plasma apoB-containing lipoproteins.

Trib1Δhep mice have significantly decreased hepatic Ldlr mRNA and protein.
Given the substantial defect in clearance of apoB-containing lipoproteins in Trib1Δhep mice,
we measured hepatic Ldlr mRNA and protein abundance. The LDLR is a key regulator of
hepatic apoB catabolism and genetic variants that reduce LDLR expression or function in
humans leads to elevated plasma LDL cholesterol levels [3]. Both male and female
Trib1Δhep mice on chow diets had significantly reduced hepatic expression of Ldlr mRNA
compared with control mice (Figure 3.11 A, C), as well as reduced levels of LDLR protein
(Figure 3.11 B, D). Thus, deletion of Trib1 in mouse hepatocytes resulted in substantial
downregulation of the LDLR, providing a molecular basis for the impaired clearance of
apoB containing lipoproteins.
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Hepatic deletion of Trib1 in the absence of Ldlr has increased lipids, but no effect
on LDL-apoB or VLDL-ApoB clearance.
To determine whether the effects of Trib1 deletion on the clearance of apoB-containing
lipoproteins were mediated solely by downregulation of the Ldlr, we generated a Trib1flox/flox
;Ldlr KO mice and injected them with AAV8-CRE or AAV8-NULL, permitting the
comparison of Trib1Δhep to Trib1 WT mice on the background of Ldlr deficiency. Hepatic
Trib1 mRNA levels showed the expected >95% reductions of Trib1 in Trib1Δhep;Ldlr KO
mice and Ldlr mRNA and protein levels were undetectable in both groups compared to
controls (Figure 3.12 A-B). We measured plasma lipids and found that deletion of Trib1 in
hepatocytes in the absence of Ldlr further increased plasma triglycerides, total cholesterol,
HDL cholesterol and non-HDL cholesterol (Figure 3.12 C-F). Fractionation of plasma by
FPLC revealed that triglycerides and total cholesterol were increased in the VLDL and
LDL fractions (Figure 3.12 G-H).
We also performed LDL-apoB and VLDL-apoB kinetic studies in the three groups of mice.
As expected, the turnover of both LDL-apoB and VLDL-apoB was markedly slower in Trib1
WT;Ldlr KO mice compared with control mice (Figure 3.13). However, deletion of hepatic
Trib1 in the absence of the LDLR had no further effect on clearance of LDL-apoB and
VLDL-apoB (Figure 3.13). These data indicate that the effect of Trib1 deletion on apoBcontaining lipoprotein clearance is dependent on Ldlr. However, these results also indicate
that Trib1 deletion increases steady state plasma lipids in a mechanism that is
independent of its regulation of apoB clearance.
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Trib1Δhep mice have increased secretion of triglyceride-poor apoB containing
lipoproteins from the liver and increased hepatic endoplasmic reticulum (ER)
stress.
The previous results suggested that hepatic Trib1 modulates apoB clearance through its
regulation of Ldlr, but that steady state lipids are regulated through an independent
mechanism. Previous studies have suggested that Trib1 regulates the levels of VLDL
secretion from the liver and we decided to test this in our model. We performed newly
synthesized apoB secretion studies by administration of pluronic to inhibit lipoprotein
lipolysis and found that Trib1Δhep mice have significantly increased apoB secretion despite
having no difference in triglyceride secretion (Figure 3.14 A-B). We also measured apoB
secretion in the context of the Ldlr KO background and observed the same results (Figure
3.14 C-D). The increase in apoB secretion without an increase in triglyceride secretion
suggested that a relatively triglyceride-poor apoB-containing lipoprotein is being secreted
by the Trib1Δhep hepatocytes. To test this, we pooled post-pluronic plasma from the newly
synthesized

apoB

secretion

experiments

and

performed

sucrose

density

ultracentrifugation to separate the lipoproteins based on their density. This experiment
showed a shift of the newly synthesized apoB in the Trib1Δhep mice toward the LDL density
fractions compared with control mice (Figure 3.14E), consistent with the secretion of more
dense apoB-containing lipoproteins. Because changes on ER stress are known to affect
the secretion of apoB lipoprotein particles [147], we assessed pEIF2a, a known marker of
ER stress, and found it to be markedly increased in Trib1Δhep mice independent of Ldlr
genotype (Figure 3.14 F-G). We conclude that hepatocyte-specific Trib1 deletion results
in increased secretion of apoB as more dense particles, exacerbating the increase in

42

plasma LDL cholesterol and apoB levels beyond the contribution of delayed LDL-apoB
clearance.
DISCUSSION

In the last decade, GWAS have served as a strong method to identify new genetic targets
for cardiometabolic diseases. The 8q24 locus, near the TRIB1 gene, was one of the first
and most strongly associated loci for all 4 major plasma lipids traits and well as CAD [69].
Additionally, this locus has also been associated with levels of ALTs and the development
of hepatic steatosis [124, 146, 148]. Since all these associations came to light, TRIB1 has
been the target of multiple studies with the goal of investigating its direct association with
plasma lipid traits as well as the possible mechanisms of action. Our group was the first
one to show direct association of Trib1 with plasma lipid regulation in vivo using mouse
models. Using an AAV-mediated Trib1 hepatic overexpressing system, mice had a
decrease in plasma lipids and hepatic lipogenesis [125]. We also demonstrated that Trib1
liver specific deletion in mice leads to increases in plasma lipids, hepatic lipogenic gene
expression and de novo lipogenesis, which lead to hepatic steatosis development [104].
However, more questions regarding TRIB1 effect on other lipoprotein metabolism
pathways remain unanswered.
In this study, I confirmed that hepatic deletion of Trib1 in mice increases plasma levels of
total cholesterol, HDL cholesterol and non-HDL cholesterol in a chow diet. Additionally, I
showed that this accumulation of lipids is specifically in the LDL triglyceride and
cholesterol fractions and that Trib1Δhep mice have an increased accumulation of apoB
proteins, the main apolipoprotein in LDL. The results from these experiments were
confirmed in male and female mice as well as in a WTD which is designed to approximate
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the "typical" human diet of North America, which makes our results biologically relevant to
human populations. We also discovered that even though Trib1Δhep mice have increased
plasma lipids, they are resistant to diet induced obesity, however the molecular
mechanism by which hepatic Trib1 might be regulating this phenotype has not been
elucidated. Previous research has suggested that in white adipose tissue (WAT), Trib1
expression is upregulated during acute and chronic inflammation in db/db mice, and Trib1
heterozygous knockout mice have impaired cytokine gene expression mediated by NF-kB
interaction in WAT, which protects them from weight gain and adiposity when fed a high
fat diet [149]. It would be interesting to study the effects of Trib1 hepatic deletion on
cytokine gene expression and to determine if a similar mechanism is responsible for the
protection against obesity in the liver. It is also possible that hepatic deletion of Trib1 might
have secondary effects on other tissues such as WAT, and that might be mediating this
phenotype.
Variants within the TRIB1 locus have been repeatedly associated with the develop of
hepatic steatosis in humans [146, 148]. Consistent with this association, Trib1Δhep mice
showcase an increased liver to body weight ratio that is characterized by increased
hepatic triglyceride and cholesterol compared to control mice. Trib1Δhep mice also
presented strikingly high levels of plasma ALTs, which is an enzyme that is produced by
the liver and its levels can increase when liver cells are damaged, so its levels can be
used to evaluate the condition of the liver [150]. Additionally, Trib1Δhep mice had
significantly low levels of plasma albumin. Albumin is a protein that is produced by the
liver and serves as a transport protein to helps carry vitamins, enzymes, and other
important substances in the circulation, and it is also used to determine liver health [151].
Certain liver diseases, such as cirrhosis, are characterized by decreased albumin levels,
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as well as impaired albumin function [151]. Overall, Trib1Δhep mice have increased hepatic
lipids and dysregulated markers of liver health, which align with the GWAS associations
with the development of hepatic steatosis.
We demonstrated that hepatic deletion of Trib1 in mice impairs postprandial lipemia, which
leads to accumulation of triglycerides in the LDL lipoprotein fractions.

We also

demonstrated that accumulation of total cholesterol in the LDL lipoprotein fractions
Trib1Δhep mice is due to the improper catabolism of LDL and VLDL lipoproteins and most
importantly, we demonstrated that the improper catabolism of these lipoproteins is due to
a decrease of the Ldlr mRNA and protein levels. As mentioned before, the LDLR is the
main receptor that mediates the clearance of plasma LDL-C from the circulation to the
liver, and it is well known that mutations that interfere with LDLR function lead to elevated
plasma LDL-C levels which are associated with increased risk of cardiovascular disease.
Prior to my investigation, hepatic TRIB1 had not been directly associated with the
regulation of the LDLR, but some studies suggested a possible interaction. One group
discovered that the small molecule compound BRD0418 upregulates TRIB1 expression
in HepG2 cells [152]. BRD0418 was able to suppress triglyceride synthesis and apoB
secretion, in addition to downregulating the expression of MTP and APOC3, both key
components of the lipoprotein assembly pathway, as well as it was shown to modulate
cholesterol metabolism in hepatic cells by elevating the expression of the LDLR transcript
and protein [152]. These phenotypes were phenocopied by TRIB1 cDNA overexpression,
however, the effects of BRD0418 persisted in TRIB1-null cells, indicating that TRIB1 is
sufficient but not necessary to transmit the effects of the drug [152]. Another group
discovered that the compound Berberine, which is a natural lipid lowering drug that
reduces plasma LDL cholesterol, total cholesterol and triglycerides in hyperlipidemic
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patients and in mice by mechanisms involving upregulation of LDLR, is able to upregulate
the levels of Trib1 mRNA [153]. The increase in Trib1 mRNA expression was associated
with reduced expression of lipogenic genes including Cebpa, Acc1 and Scd1. However,
Berberine treatment was able to reduce plasma lipids in mice in a wild type background
as well as in a hypercholesterolemic Ldlr deficient mice, suggesting that the role of Trib1
in the Berberine mediated triglyceride lowering is independent of LDLR regulation [153].
Furthermore, a group that studies circadian regulation of lipid associated genes
demonstrate that ablation of the liver clock in mice perturbs diurnal regulation of lipidassociated genes in the liver and markedly reduced the expression of the gene Trib1, and
that Trib1 rescue experiments lowered PCSK9 levels, increased LDLR protein expression
and restored plasma cholesterol homeostasis in mice lacking a functional liver clock [154].
Their results illustrated a mechanism by which the biological clock regulates cholesterol
metabolism and the expression of the Ldlr by regulating non-clock genes such as hepatic
Trib1.
My studies show that hepatic Trib1 can regulate plasma lipid metabolism both
independently and by its regulation of the LDLR (Figure 3.15). I demonstrated that hepatic
Trib1 is able to regulate the clearance of apoB containing lipoproteins through its
regulation of LDLR, but that steady state plasma lipids are regulated independently of the
LDLR. As Trib1 expression has been previously associate with the regulation of
triglyceride production and VLDL secretion from the liver, we decided to explore if this is
the mechanism by which Trib1 is regulating steady state plasma lipids independently of
LDLR regulation. Indeed, we demonstrated that in the absence of the Lldr, Trib1 deletion
is able to further increase the secretion of apoB lipoproteins from the liver, a phenotype
that was also observed in Trib1 hepatic deleted mice in a wild type background.
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Surprisingly, the increased in apoB secretion was not accompanied by an increase in
triglyceride secretion from the liver, which suggest that hepatic deletion of Trib1 leads to
the secretion of triglyceride depleted apoB containing lipoproteins. This was a striking
finding considering that Trib1Δhep mice have increased levels of triglycerides in their
hepatocytes, however this triglyceride is not being incorporated into the newly formed
VLDL particles. This finding was also surprising because the secretion of VLDL-apoB is a
tightly regulated process by the Endoplasmic-reticulum-associated protein degradation
(ERAD) complex, which targets improperly folded or improperly lipidated apoB proteins
for ubiquitination and proteasomal degradation [147, 155]. In our studies we showed that
hepatic deletion of Trib1 results in increased ER stress in hepatocytes, which has been
previously associated with increased apoB secretion from hepatocytes. However, more
questions regarding the mechanism by which Trib1 hepatic deletion results in the
secretion of smaller VLDL particles as well as the molecular mechanism by which hepatic
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FIGURES

Figure 3. 1: Hepatic Trib1 mRNA levels in Trib1Δhep mice relative to control mice.
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Figure 3.1: A-D. Hepatic transcript levels of Trib1 in chow-fed male mice (n=5) 8 weeks
after injection (A), 22 weeks post deletion (following 17 weeks on WTD) (B), in chow-fed
female mice (n=5) 4 weeks after injection (C) and female mice (n=5), 22 weeks post
injection and following 17 weeks of WTD feeding. Box plots indicate median, 25th and
75th percentiles with whiskers extending to minimum and maximum values. Symbols
indicate single values. Significance was determined by two-tailed, unpaired Student’s t
test (***p ≤ 0.001; ****p ≤ 0.0001).
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Figure 3. 2: Hepatic Deletion of Trib1 increases plasma cholesterol in male mice.
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Figure 3.2: A- D. Plasma triglycerides, total cholesterol, HDL-cholesterol and non-HDL
cholesterol levels in chow-fed Trib1Δhep male mice 4 weeks post-deletion, (n=5). Box plots
indicate median, 25th and 75th percentiles with whiskers extending to minimum and
maximum values. Symbols indicate single values. Significance was determined using twotailed, unpaired Student’s t-test (*p≤0.05). E-H. Plasma triglycerides, total cholesterol,
HDL-cholesterol and non-HDL cholesterol levels at indicated timepoints over 18 weeks of
WTD-feeding (n=8). Data are expressed as mean ± s.e.m for the experimental group.
Significance was determined using 2-way ANOVA with Tukey’s multiple comparisons test
(****p≤0.0001).
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Figure 3. 3: Hepatic deletion of Trib1 increases plasma cholesterol in female mice.
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Figure 3.3: A-D. Plasma triglycerides, total cholesterol, HDL-Cholesterol and non-HDL
cholesterol levels 2 weeks post-deletion on chow diet mice (n=5). Box plots indicate
median, 25th and 75th percentiles with whiskers extending to minimum and maximum
values. Symbols indicate single values. Significance was determined using two-tailed,
unpaired Student’s t-test (*p≤0.05, **p≤0.01). E-H. Plasma triglycerides, total cholesterol,
HDL-cholesterol and non-HDL cholesterol levels at selected timepoints over 17 weeks on
WTD, (n=5). Data are expressed as mean ± s.e.m for the experimental group. Significance
was determined by one-way ANOVA with Tukey’s multiple correction test (*p ≤ 0.05; **p
≤ 0.01,***p ≤ 0.001; ****p ≤ 0.0001).
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Figure 3. 4: Hepatic deletion of Trib1 increases plasma ApoB protein levels in
male mice.
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Figure 3.4: A-B. Immunoblots of ApoB protein in plasma from chow-fed mice 4 weeks
post deletion (A), and mice fed WTD for 11 weeks. (B). Equal volumes of plasma were
loaded in each well and gel was run for 3hrs at 90volts to properly separate apoB 100
from apoB 48.
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Figure 3. 5: Hepatic deletion of Trib1 increases plasma LDL lipoprotein fractions in
male mice.
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Figure 3.5: A-B. FPLC was performed on pooled plasma from male mice fed chow for 6
weeks and C-D. mice fed WTD for 12 weeks to separate lipoproteins based on their size.
Triglycerides (A, C) and total cholesterol (B, D) concentrations were measured in all
fractions.
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Figure 3. 6: Hepatic deletion of Trib1 increases plasma LDL lipoprotein fractions in
female mice.
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Figure 3.6: A-B. FPLC was performed on pooled plasma from female mice fed chow for
8 weeks and C-D. mice fed WTD for 12 weeks to separate lipoproteins based on their
size. Triglycerides (A, C) and total cholesterol (B, D) concentrations were measured in all
fractions.
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Figure 3. 7: Hepatic deletion of Trib1 protects against diet induced obesity and show indications of liver damage.
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Figure 3.7: A. Changes in body weight during chow (weeks 0-5) and WTD (weeks 6-23)
feeding (n=8). B. Liver to body weight ratio in chow fed mice 8 weeks post deletion (n=5).
Hepatic triglyceride (C.) and total cholesterol (D.) levels in chow fed mice 8 weeks post
deletion (n=5). E. Plasma ALT levels at indicated timepoints over 22 weeks of chow and
WTD-feeding (n=8). F. Plasma Albumin levels in chow fed mice 4 weeks post deletion
(n=5). A,E. Data are expressed as mean ± s.e.m for the experimental group. Significance
was determined using 2-way ANOVA with Tukey’s multiple comparisons test. B,C,D,F.
Box plots indicate median, 25th and 75th percentiles with whiskers extending to minimum
and maximum values. Symbols indicate single values. Significance was determined using
two-tailed, unpaired Student’s t-test. For all the results: *p≤0.05, **p≤0.01, ****p≤0.0001.
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Figure 3. 8: Hepatic deletion of Trib1 impairs post-prandial triglyceride clearance
in male and female mice.
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Figure 3.8: A-B. OFTT in male mice after 5 weeks on chow (A) and 5 weeks on WTD
(B). C. AUC calculation for A and B. D-E. OFTT in female mice after 5 weeks on chow (D)
and 6 weeks on WTD (E). F. AUC calculation for D and E. Data are expressed as mean
± s.e.m for the experimental group. Significance was determined using 2-way ANOVA with
Tukey’s multiple comparisons test (*p≤0.05, **p≤0.01, ***p≤0.001).
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Figure 3. 9: Hepatic deletion of Trib1 impairs LDL and VLDL apoB clearance in
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Figure 3. 9: A-B. LDL clearance in chow-fed mice 8 weeks after AAV injection (n=5) and
C-D. WTD-fed mice for 19 weeks (24 weeks post AAV injection). A-D. Mice were injected
with

125

I-radiolabeled LDL isolated from human plasma. Clearance of

125

I-LDL was

determined by measuring residual 125I-activity at different time-points after injection (2 min24 hour); residual

125

125

I-activity is expressed as fraction of the total

I-activity, 2 min after

injection. B, D. Fractional catabolic rate (FCR) of LDL from A and C, this is calculated from
the reciprocal of the area under a fitted biexponential curve; and represents fraction of
LDL cleared per hour. Results were confirmed in an independent cohort in chow fed mice
and 2 independent cohorts in WTD fed mice. E. VLDL clearance in chow-fed male mice 8
weeks after AAV injection. Mice were injected with125I-radiolabeled human VLDL. Plasma
was sampled at intervals over a period of 24 hours and the total remaining counts were
normalized to the injected dose at 1 minute post injection of

125

I- VLDL. F.FCR of

125

I-

VLDL. A, C, D. Data are expressed as mean ± s.e.m for the experimental group. B, D, F.
Box plots indicate median, 25th and 75th percentiles with whiskers extending to minimum
and maximum values. Symbols indicate single values. Significance was determined using
two-tailed, unpaired Student’s t-test (*p≤0.05, ***p≤0.001, ****p≤0.0001).
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Figure 3. 10: Hepatic deletion of Trib1 impairs LDL apoB clearance in female mice.
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Figure 3.10: A-B. LDL clearance in chow-fed mice 10 weeks after AAV injection (n=5)
and C-D. WTD-fed mice for 19 weeks (24 weeks post AAV injection). B, D. FCR of LDL
from A and C is calculated from the reciprocal of the area under a fitted biexponential
curve and represents fraction of LDL cleared per hour. A, C. Data are expressed as mean
± s.e.m for the experimental group. B, D. Box plots indicate median, 25th and 75th
percentiles with whiskers extending to minimum and maximum values. Symbols indicate
single values. Significance was determined using two-tailed, unpaired Student’s t-test
(*p≤0.05).
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Figure 3. 11: Hepatic deletion of Trib1 reduces Ldlr mRNA and protein levels in
male and female mice.
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Figure 3.11. A. Hepatic transcript levels of Ldlr in chow fed male Trib1Δhep mice relative to
control mice 8 weeks after AAV injection (n=5). B. Hepatic protein levels of LDLR and βactin in control and Trib1Δhep mice (n=5) from mice in A. C. Hepatic transcript levels of Ldlr
in female Trib1Δhep mice relative to control mice 8 weeks after AAV injection (n=3 and 4).
D. Hepatic protein levels of LDLR and β-actin in control and Trib1Δhep mice (n=5) from mice
in C. Box plots indicate median, 25th and 75th percentiles with whiskers extending to
minimum and maximum values. Symbols indicate single values. Significance was
determined using two-tailed, unpaired Student’s t-test (**p≤0.01).
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Figure 3. 12: Hepatic deletion of Trib1 in the absence of Ldlr increases steady
state plasma lipids.
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Figure 3.12: A. Hepatic mRNA levels of Trib1 and Ldlr in male mice (n=5) 8 weeks post
deletion. B. Hepatic LDLR and Actin protein levels in male mice 8 weeks post deletion. CF. Plasma triglycerides, total cholesterol, HDL Cholesterol and non-HDL cholesterol levels
in chow-fed male mice 4 weeks post-deletion. G-H. FPLC of triglyceride and total
cholesterol performed on pooled plasma from chow fed mice for 6 weeks after AAV-CRE
injection. Box plots indicate median, 25th and 75th percentiles with whiskers extending to
minimum and maximum values. Symbols indicate single values. Significance was
determined using ordinary One-way ANOVA with multiple comparisons test (*p≤0.05,
****p≤0.0001).
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Figure 3. 13: Hepatic deletion of Trib1 in the absence of Ldlr increases steady
state plasma lipids.
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test (****p≤0.0001).
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Figure 3. 14: Hepatic deletion of Trib1 in the absence of Ldlr increases steady
state plasma lipids due to increase in the hepatic secretion of ApoB
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Figure 3.14: A, C. Quantification of apoB levels in plasma collected at 1.5 hours after
injection with P407 and 200 μCi of

35

S methionine-cysteine. Box plots indicate median,

25th and 75th percentiles with whiskers extending to minimum and maximum values.
Symbols indicate single values. B, D. Triglyceride production over time after injection with
P407 and 200 μCi of

35

S methionine-cysteine. Data are expressed as mean ± s.e.m for

the experimental group. Significance was determined by one-way ANOVA with Tukey’s
multiple correction test (*p≤0.05, **p≤0.01, ***p ≤ 0.001). E. ApoB 100 protein from pooled
plasma samples separated by sucrose density gradient after injection with P407 and 200
μCi of 35S methionine-cysteine, raw quantification of ApoB100 levels and fractional
distribution of ApoB100 across the gradient. F. Hepatic pEIF2a and Actin protein levels in
male mice 4 weeks post deletion. G. Hepatic pEIF2a and Actin protein levels in male mice
8 weeks post deletion.
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Figure 3. 15: Role of Hepatic Trib1 in the regulation of LDL-apoB.

Figure 3.15: A. Simplified diagram of the endogenous lipoprotein metabolism pathway.
Circulating lipids are highly regulated by the rates of production and secretion from the
liver in the form VLDL. VLDL is then hydrolyzed in the capillaries mediated by LDL which
converts them into LDL lipoproteins. LDL particles are then cleared to the liver mediate by
the LDLR and other related receptors. B. Trib1 hepatic deletion increases LDL-apoB levels
by increasing the rates of ApoB production independently of the LDLR-mediated clearance
of LDL-apoB.
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CHAPTER 4:
Hepatic TRIB1 regulates LDL metabolism through CEBPA-mediated regulation of
the LDL receptor.

ABSTRACT
The TRIB1 gene, a GWAS signal for plasma lipids and CAD, has been broadly
demonstrated to regulate plasma lipids in cell and animal models. In the previous chapter
I demonstrated that murine hepatic Trib1 regulates the rates of lipoprotein secretion from
the liver as well as the rate of apoB containing lipoprotein clearance mediated by the LDLR
in hepatocytes. Since TRIB1’s most studied molecular function is the interaction with the
E3 ubiquitin ligase COP1 to target the transcription factor CEBPA for ubiquitination and
proteasomal degradation, we decided to explore if this interaction is responsible for TRIB1
effects on the LDLR. The results from my studies showed that simultaneous deletion of
Cebpa in Trib1Δhep mice (Trib1Δhep;CepbaΔhep/ DKO mice), eliminated the effects of hepatic
deletion of Trib1 on plasma lipids, hepatic lipids, ALTs, apoB catabolism and hepatic LDLR
regulation. We used RNA sequencing analysis to explore the mechanism by which
hepatic Trib1 regulates the Ldlr in a CEBPA-dependent manner and found that Activating
Transcription Factor 3 (Atf3) was highly upregulated in the livers of Trib1Δhep but not DKO
mice. ATF3 is a stress-inducible transcriptional repressor that interacts with the promoter
region of LDLR and represses its expression; furthermore, ATF3 directly binds to the
CEBPA protein. We also demonstrated that downregulating Atf3 in Trib1Δhep mice reduced
the plasma levels of total cholesterol, HDL- cholesterol and LDL-cholesterol, and partially
attenuated the effects on the LDLR. Based on these data, we conclude that hepatic
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deletion of Trib1 leads to a post-translational increase in CEBPA, which drives Atf3
expression, leading to the downregulation of the Ldlr and increased plasma LDL
cholesterol. Our studies address a new regulatory interplay between TRIB1 and CEBPA
in liver and the mechanisms by which TRIB1 regulates LDL cholesterol and lipoprotein
metabolism.
INTRODUCTION
The tribbles gene was first identified in Drosophila as a regulator of cell division and
morphogenesis and was shown to regulate the proteins encoded by the string and slbo
genes, the Drosophila homologs of the dual phosphatase CDC25A, and CEBPA
respectively [88, 89, 91]. Since its discovery, 3 homologs have been identified in humans
(TRIB 1-3). The TRIB family of genes encode pseudokinase proteins that are highly
conserved through different species [93]. These proteins are highly homologous to
serine/threonine kinases yet lack residues that make them catalytically inactive [92-94].
TRIB family members instead can serve as a signal transductor modulator or scaffolding
protein for important cellular processes. Some of these processes include the interaction
with mitogen- activated protein kinase kinase (MAPKK) and further phosphorylation of
ERK1/2 targets and the interaction with the ubiquitin ligate COP1 protein to target the
transcription factors CCAAT enhancer- binding proteins alpha and beta (CEBP α/β) for
proteasomal degradation [92-94]. TRIB1, the main gene studied in this dissertation, has
been proposed to interact and regulate a variety of protein targets, including SAP18Sin3A, HNF4A and ChREBP [134, 136, 137], however, regulation of the COP1-CEBPA
axis remains the most fully described function of TRIB1 [102, 112].
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CEBPA is well known for its function as a regulator of myeloid cell development and
hematopoiesis, however is also highly expressed in adipose tissue and the liver in mouse
and humans, and has been broadly described as regulator of adipogenesis, critical for
glucose and lipid homeostasis and for the regulation of several metabolic genes in the
liver [106, 109, 110, 128, 156]. Bauer et al. [104] demonstrated that hepatic deletion
of Trib1 in mice results in increased hepatic triglyceride content, lipogenic gene
expression, de novo lipogenesis and increased plasma lipids. These mice also displayed
an increased in hepatic CEBPa protein, which was shown to be both necessary and
sufficient to drive the lipogenic phenotype in Trib1 hepatic deleted mice, establishing
CEBPa as the mechanistic link between TRIB1 and hepatic lipogenesis regulation
[104]. However, the association of CEBPa and its possible involvement in the regulation
of plasma lipids in this model was not fully elucidated. The main goal of these studies was
to elucidate if Trib1 regulation of CEBPa protein is involved in the regulation of plasma
lipids, ALTs, apoB catabolism and LDLR regulation in mice.
I demonstrated that deletion of Cebpa in Trib1Δhep mice eliminated the effects of hepatic
deletion of Trib1 on plasma lipids, hepatic lipids, ALTs, apoB catabolism and hepatic LDLR
regulation. Also, through RNA sequencing analysis, we uncovered a novel binding factor
mediating TRIB1 regulation of the LDLR in a CEBPA-dependent manner, the Activating
Transcription Factor 3 (ATF3), which was highly upregulated in the livers of Trib1Δhep but
not in DKO mice. ATF3 is a stress-inducible gene that encodes a member of the
ATF/CREB family of transcription factors, which share a basic-region leucine zipper (bZip)
DNA binding domain [157-159]. ATF3 expression is low in cells under steady-state
conditions and is induced by a variety of extracellular stimuli, such as proinflammatory
cytokines, nitric oxide, high concentrations of glucose and palmitate, and endoplasmic
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reticulum (ER) stress [160-163]. A previous study using human liver Sk-Hep1 cells
provided evidence that increased ER stress response or disturbance of mitochondrial
function leads to the activation of ATF3, which causes a reduction on LDLR expression
[164]. We also demonstrated that downregulating Atf3 in Trib1Δhep mice reduced the levels
of total cholesterol, HDL- cholesterol and LDL-cholesterol, and partially attenuated the
effects on the LDLR. Based on our results and previous literature findings we conclude
that increased Atf3 expression in the livers of Trib1Δhep mice is leading to the down
regulation of the LDLR expression in a sterol-independent mechanism.

RESULTS

Efficient hepatocyte-specific deletion of Trib1 and Cebpa in Trib1Δhep, CepbaΔhep and
DKO mice.
It has been previously shown that hepatic deletion of Trib1 in mice leads to increased
hepatic CEBPA protein levels, and that this increase in CEBPA was sufficient to induce
increased de novo lipogenesis and hepatic steatosis in mice. However, the association of
TRIB1 and CEBPA and their regulation of plasma lipids has not been fully elucidated. In
order to determine if increased CEBPA protein is necessary for the effects of hepatic Trib1
deletion on plasma lipids, apoB kinetics and LDLR regulation, we turned to a different
model. For this, we crossed our Trib1flox/flox mice to a Cebpaflox/flox mice line with the goal of
creating a DKO model. In these studies, we compared C57BL/6J wild type (control) mice
to Trib1Δhep, CepbaΔhep and DKO mice, all groups were injected with AAV-CRE. As
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expected, liver Trib1 and Cebpa mRNA levels showed the expected >95% reductions of
Trib1 in Trib1Δhep mice and Cebpa in CebpaΔhep mice (Figure 4.1A). We also observed a
70% reduction of Trib1 mRNA in CebpaΔhep mice and a 65% reduction of Cebpa mRNA in
Trib1Δhep mice (Figure 4.1A). In contrast to the reduction in Cebpa mRNA, the Trib1Δhep
mice had a substantial increase in CEBPa protein, particularly the p30 isoform (the isoform
which is highly expressed centain patients with AML), whereas CebpaΔhep and DKO mice
completely lacked CEBPa protein, as expected (Figure 4.1B). These findings are
consistent with a post-translational effect of TRIB1 on CEBPA in promoting its
degradation, as well as that TRIB1 and CEBPA participate in a tight feedback loop, where
more CEBPA protein leads to increased TRIB1 transcription and TRIB1 targets CEBPA
for degradation.

Hepatic deletion of Cebpa in Trib1Δhep mice decreases plasma cholesterol and LDL
lipoprotein fractions levels.
We then went on to explore the effects of Cebpa deletion by itself as well as in the absence
of hepatic Trib1 on plasma lipids. As shown in my previous studies Trib1Δhep mice had
increased plasma total cholesterol, HDL-C and non-HDL-C, both on chow and WTD
(Figure 4.2). CebpaΔhep mice had normal to decreased levels of triglycerides, total
cholesterol, HDL-C and non-HDL-C in both chow (Figure 4.2 A-D) and WTD (Figure 4.2
E-H) as well as triglycerides and total cholesterol in the LDL fractions on chow and WTD
feeding (Figure 4.3) when compared to control mice, further corroborating CEBPa
involvement in the regulation of plasma lipids. Most interestingly, deletion of Cebpa in
Trib1Δhep mice eliminated the increase in total cholesterol, HDL cholesterol and non-HDL
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cholesterol on both chow (Figure 4.2 A-D) and WTD (Figure 4.2 E-H). Deletion of Cebpa
in male Trib1Δhep mice also completely eliminated the increase in triglycerides and total
cholesterol in the LDL fractions in a chow diet (Figure 4.3 A-B), and these effects were
further amplified when the mice were challenged with a WTD (Figure 4.3 C-D) to levels
similar to control mice or lower. These data prove that hepatic CEBPA protein itself is
important for the regulation of plasma lipids, and that hepatic CEBPA protein is required
for the phenotypic effect of hepatic Trib1 deletion causing increased plasma lipids.

Hepatic deletion of Cebpa in Trib1Δhep mice normalizes liver lipids, ALTs and
Albumin levels.
My previous studies revealed that Trib1Δhep mice have increased hepatic triglycerides and
total cholesterol, increased ALTs and deceased Albumin protein levels (Figure 4.4). I
demonstrated that Cebpa Δhep mice had normal levels of hepatic lipids, ALTs and increased
albumin levels, and that hepatic deletion of Cebpa in Trib1Δhep mice eliminated the
increased levels of hepatic lipids and circulating ALTs, and increased albumin levels back
to control mice levels (Figure 4.4). These data prove that increased hepatic CEBPa protein
is required for the phenotypic effect of Trib1Δhep causing increased liver lipids, increased
ALTs and decreased albumin levels, all of which are markers of impaired liver health.
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Hepatic deletion of Cebpa in Trib1Δhep mice improves the clearance of postprandial
plasma triglycerides
As shown in my previous studies, even though Trib1Δhep mice have no changes in steady
state plasma triglycerides, they accumulate triglycerides on the LDL lipoprotein fractions,
indicated by improper postprandial lipemia measured by OFTT. To test if Trib1 regulation
of CEBPa protein mediates this effect in postprandial lipemia, we performed OFTT studies
in these cohorts. Here, I confirmed that Trib1Δhep mice have impaired triglyceride clearance
after challenge with an oral fat load (Figure 4.5). I also showed that CebpaΔhep mice have
improved triglyceride clearance compared to control mice, and that hepatic deletion of
Cebpa in Trib1Δhep mice eliminated the impairment of triglyceride clearance compared to
Trib1Δhep mice and resulted in improved clearance compared to control mice, which was
confirmed by a decreased area under the curve (Figure 4.5). Thus, increased CEBPa
protein is necessary for the postprandial lipemia phenotype we previously observed in
Trib1Δhep mice.

Hepatic deletion of Cebpa in Trib1Δhep mice improves the clearance of LDL- apoB
and VLDL-apoB and normalizes the levels of the LDL-Receptor.
We then tested if Trib1 effects on apoB catabolism was mediated through its regulation of
CEBPa by injecting mice with
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I labeled human isolated LDL or VLDL. As I showed

before, Trib1Δhep mice exhibited markedly slower LDL and VLDL catabolism calculated by
its fractional catabolic Rate (Figure 4.6 A-D). Cebpa Δhep mice had normal LDL and VLDL
apoB catabolism, and what was more interesting is that DKO mice also had normal LDL
and VLDL catabolism (Figure 4.6 A-D), suggesting that increased CEBPa protein is also
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necessary for the Trib1 deletion effect on apoB catabolism. As this defect in apoB
catabolism was mediated by the LDLR in Trib1Δhep mice, we assessed changes in the Ldlr
mRNA and protein levels in the CebpaΔhep cohorts. Trib1Δhep mice recapitulated the
decrease in Ldlr mRNA and protein levels (Figure 4.6 E-F). Even though CebpaΔhep mice
had decreased Ldlr mRNA, their LDLR protein levels were comparable to control mice
(Figure 4.6 E-F) and more interesting deleting Cebpa in the absence of Trib1 was not able
to decrease the levels of Ldlr mRNA and protein levels (Figure 4.6 E-F). These data
support that hepatic CEBPa protein is required for the phenotypic effect of hepatic Trib1
deletion causing reduced Ldlr expression and impaired apoB-lipoprotein catabolism,
leading to hypercholesterolemia. Thus, the increased CEBPa protein in hepatocytes due
to loss of Trib1 likely leads to reduced Ldlr expression.

Numerous Trib1 genetics effects are mediated through its regulation of Cebpa
The abundance of hepatic LDLR protein is tightly regulated to ensure normal cellular
function, at both the transcriptional and post-transcriptional levels. To gain further insight
about the molecular mechanism by which TRIB1 regulation of CEBPA leads to changes
in the LDLR expression, we performed whole transcriptome RNA sequencing in livers from
chow-fed control, Trib1Δhep, CebpaΔhep and DKO mice. Volcano plot summaries of changes
in gene expression between all groups can be found in Figure 4.7- 4.8. A total of 14,937
transcripts were differentially expressed between all groups, excluding transcripts with
missing values. Out of these, 7,458 were upregulated (a positive Fold-Change relative to
WT log2FC), and 7,479 were downregulated (negative log2FC) in Trib1Δhep mice
compared with control mice. Out of these, 916 transcripts (464 up, 452 down) were altered
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by more than 1.5-fold between Trib1Δhep and control mice (absolute log2FC>0.6, adjusted
p-value <0.00001) (Figure 4.7A, Figure 4.8A). Of the 916 differentially expressed
transcripts, only 75 met the same adjusted p-value (<0.00001) cut-off in DKO mouse liver
mRNA (Figure 4.7B, Figure 4.8B), indicating that the vast majority (91.8%) of the
significant gene expression changes in Trib1Δhep mouse liver were attributable to
dysregulation of CEBPA levels. DKO mouse livers were much more similar to control mice
(Figure 4.7B) and the comparison between Cebpaflox/flox and DKO showed the fewest
changes (Figure 4.7D), consistent with the critical role of elevated CEBPA protein in
mediating the effects of Trib1 deletion in liver on gene expression.

Trib1’s CEBPa dependent regulation of the LDLR is mediated independently of
SREBPs canonical pathways
We mined the RNA-seq data for transcriptional regulators upstream of Ldlr that were
significantly altered by Trib1 deletion that were dependent on CEBPa. We noted only
modest changes in the expression of the genes encoding the SREBP1 and 2 proteins and
noted that these were not dependent on CEBPa (Figure 4.9). Srebf1 mRNA levels were
unchanged when comparing all groups (Figure 4.10 A), and SREBP1 protein levels were
modestly increased in Trib1Δhep, which is the opposite directionality expected for the
observed effect on LDLR (Figure 4.10B). Srebf2 mRNA were decreased in Trib1Δhep as
well as in DKO mice (Figure 4.10C). However, levels of mature SREBP2 did not differ
between the Trib1Δhep and control mice (Figure 4.10D). Interestingly, the DKO livers had
almost complete loss of mature SREBP2, which may account for the fact that their plasma
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cholesterol levels are lower than controls. These results suggest that the canonical
SREBP pathway has a relatively minor impact on LDLR in hepatocytes of lacking Trib1.

Trib1’s CEBPA dependent regulation of the LDLR is mediated by ATF3.
After mining the RNA-seq data for transcriptional regulators upstream of Ldlr significantly
altered by Trib1 deletion that were dependent on CEBPA, we identified a potential target
that could explain the effects of Trib1 on the LDLR in a CEBPa dependent manner, the
Activating Transcription Factor 3 (ATF3). ATF3 is a stress-inducible transcriptional
repressor that belongs to the ATF/cAMP-response element-binding protein family of
transcription factors [165]. ATF3 has been previously described to interact with the
promoter region of LDLR and repress its expression [164]. Additionally, ATF3 has also
been described to physically interact with the transcription factor CEBPA [166, 167]. Atf3
was one of the most highly upregulated genes in Trib1Δhep liver (Figure 4.9A, 49.3 fold
increase, adjusted p-val = 6.33E-46) and this was dependent on CEBPa, as Atf3
expression did not differ between control and DKO livers (Figure 4.9B, 1.5 fold increase,
adjusted p-value = 0.57). We confirmed these results by qPCR, finding that relative to
control, Atf3 mRNA was increased >25-fold in Trib1Δhep liver but not in DKO liver (Figure
4.11A), which was also confirmed by western blot (Figure 4.11B), indicating that increased
CEBPa is required for the upregulation of Atf3 in Trib1Δhep mice.
Additionally, through gene set enrichment we identified 54 ATF3 downstream target genes
that were differentially expressed in the Trib1Δhep mouse liver and found that these were
similarly CEBPa dependent (Figure 4.12 A-B). Pathway analysis of ATF3 interacting
genes in other datasets is shown in Figure 4.12 C-E. Furthermore, analysis of ChIP-seq
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for differential CEBPa binding sites in Trib1Δhep mouse livers confirmed that there is an
enrichment in binding motifs for ATF family members, including ATF3 and its upstream
regulator ATF4 in CEBPa bound regions (Table 2). Other factors with enriched binding
motifs included CEBPA, NFIL3, CHOP, ATF1, and ATF7 (Table 2). These results are
consistent with a model in which the deletion of Trib1 allows CEBPa protein to escape
targeted proteolysis resulting in increased CEBPa protein. The increased CEBPa protein
directly interacts with the Atf3 promoter and leads to its transcriptional upregulation, which
then binds the Ldlr promoter and represses its activity thereby resulting in the
downregulation of Ldlr mRNA and protein levels.

Knockdown of Atf3 in Trib1Δhep mice decreases total cholesterol and HDL
cholesterol and increased LDLR protein.
To test the model that Trib1 regulation of the LDL receptor is mediated by CEBPa and its
effects on Atf3 expression and function, we acquired an siRNA directed against mouse
Atf3 and a non-targeting control siRNA (directed against firefly luciferase), and injected
Trib1Δhep mice with siRNAs targeted to Atf3 or luciferase and control mice with siRNA to
luciferase. Our hypothesis was that preventing Atf3 upregulation in Trib1Δhep mice would
impact LDLR protein and plasma cholesterol levels. Trib1 mRNA levels were efficiently
deleted in Trib1Δhep mice (Figure 4.13A). The mRNA abundance of Atf3 was substantially
increased in the Trib1Δhep mice receiving the control siRNA, but in the Trib1Δhep mice
receiving the Atf3 siRNA this Atf3 mRNA expression was mildly attenuated, but not
significantly (Figure 4.13B). The protein abundance of ATF3 substantially increased in the
Trib1Δhep mice receiving the control siRNA and surprisingly, in Trib1Δhep mice receiving the
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Atf3 siRNA this was attenuated to levels comparable to control mice (Figure 4.13C), even
though there was no reduction in mRNA levels. Trib1Δhep mice receiving the Atf3 siRNA
had a significant reduction in the levels of total cholesterol (Figure 4.14 A-D) and HDL
cholesterol (Figure 4.14 E-H), but no significant changes in non-HDL cholesterol or
triglycerides (Figure 4.14 I-P), compared to Trib1Δhep mice receiving the control siRNA.
Trib1Δhep mice receiving the Atf3 siRNA also had a mild reduction in the levels of LDL
cholesterol when compared to Trib1Δhep mice receiving the control siRNA (Figure 4.15 AC). The decrease in ATF3 protein did not affect the Ldlr mRNA levels (Figure 4.16 A) but
was surprisingly associated with modestly increased levels of LDLR protein compared to
mice injected with control siRNA (Figure 4.16B). This result supports the model that ATF3
contributes to the downregulation of LDLR in Trib1Δhep mice.
In summary, our experiments show that deletion of hepatic Trib1 increases plasma LDL
cholesterol levels by resulting in downregulation of the expression of the LDLR leading to
reduced LDL-apoB clearance and that this effect of TRIB1 is dependent on CEBPa. We
also identified ATF3 as at least one mediator of the effects of TRIB1 and CEBPa regulation
of LDLR expression. This study provides new functional insight into the strong genetic
association between TRIB1 and the regulation of plasma lipid levels in humans.

DISCUSSION

These studies were designed to elucidate the molecular mechanism by which murine
hepatic Trib1 regulates plasma lipids and the expression of the Ldlr. I demonstrated that
increased CEBPa protein is required for the effects of Trib1 hepatic deletion on plasma
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lipids, hepatic lipids, ALTs, albumin levels, apoB-lipoprotein clearance and Ldlr regulation.
As neither Trib1 nor Cebpa had previously been associated with the regulation of Ldlr, we
used RNA sequencing to identify possible interacting partners that might explain this
regulation.

We observed that hepatic deletion of Trib1 led to a CEBPa-dependent

increase in expression of the transcription factor ATF3, which has been shown to directly
interact with CEBPa and to independently target the promoter region of the LDLR gene
and repress its transcription (Figure 4.17). Our data reveal a novel mechanism regulating
Ldlr expression and plasma LDL-C levels, namely that reduction in hepatic Trib1 leads to
increased CEBPa protein, which results in increased mRNA and protein levels of ATF3,
which in turn leads to the downregulation of Ldlr mRNA and protein.
The LDLR is the main receptor that mediates the clearance of plasma LDL cholesterol to
the liver [3, 4]. It is well known that mutations that abrogate or cause reduction on LDLR
level or function lead to elevated plasma LDL-C levels which are associated with an
increased risk of cardiovascular disease [3, 4, 168]. Because of this, the expression of
LDLR is tightly regulated at multiple levels to ensure normal cellular function. At the
transcriptional level, it is well known that the expression of LDLR gene is mainly regulated
by sterol regulatory element-binding proteins 1 and 2 (SREBP-1, SREBP-2), this in
response to intracellular cholesterol levels [35, 36].

At the post-translational level,

regulation of LDLR is primarily governed by PCSK9 that upon binding to cell-surface
LDLR, mediates its degradation [34, 39, 40, 169]. Other non-canonical mechanism for the
LDLR regulation have been proposed, but not fully explained. RNA sequencing in the
livers of the mice in all our cohorts didn’t show major changes on the SREBP canonical
pathways that regulate the LDLR expression, confirmed by qPCR and western blots for
both SREBP-1 and SREBP-2. These results suggest that the SREBP pathways were not
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contributing to the LDLR phenotype in Trib1Δhep mice. The results from the RNA
sequencing experiments led us to explore other non-canonical pathways that had been
recently published as regulators of LDLR expression and we focused on finding
transcription factors that changed significantly in Trib1Δhep livers but were normalized in
DKO livers.
Ingenuity pathway analysis of the RNA sequencing data led to identification of Atf3, which
was substantially increased in Trib1Δhep mouse livers but unchanged in DKO livers,
indicating that its regulation by Trib1 is CEBPa dependent.

ATF3 is a stress-inducible

gene that encodes a member of the ATF/CREB family of transcription factors, which share
a basic-region leucine zipper (bZip) DNA binding domain [160, 165]. ATF3 expression is
low in cells under steady-state and is induced by a variety of extracellular stimuli, such as
proinflammatory cytokines, nitric oxide, high concentrations of glucose and palmitate, and
endoplasmic reticulum stress [160, 161, 170, 171]. ATF3 has been shown to regulate
proliferation and apoptosis under stress conditions, this by forming dimers to activate or
repress the expression of related genes [160, 165, 172, 173]. Further, ATF3 has been
associated with the modulation of the immune response, atherogenesis, cell cycle, obesity
and glucose homeostasis [170, 172, 174-177]. However, more studies are needed to
determine the tissue specific roles of ATF3 in metabolic regulation. The effects of this gene
have many similarities with the observed phenotypes of hepatic Trib1 deletion, which
makes it an interesting target for future investigation.
More interestingly, a previous study using human liver Sk-Hep1 cells provided evidence
that increased endoplasmic reticulum (ER) stress response or disturbance of
mitochondrial function leads to the activation of ATF3, which causes a reduction on LDLR
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expression [164]. They demonstrated the region between -8 and -3 of the LDLR proximal
promoter region as a putative binding site for ATF3 and confirmed their interaction by
chromatin immunoprecipitation in a stress-dependent manner [164]. Our results also
suggest that Atf3 induction and possible function in Trib1Δhep mice is mediated by the
increased in CEBPa protein, which we believe is the connecting link in the downstream
regulation of the LDLR. Previous studies focused on studying the bZIP protein-protein
interaction networks demonstrated that ATF3 physically interacts with CEBPa, and this
was demonstrated using electrophoretic mobility shift assay (EMSA), and fluorescence
resonance energy transfer (FRET) [166]. Another group used EMSA as well as ChIP
assays to demonstrated that ATF3 directly binds to the mouse CEBPa promoter,
supporting the notion of mutual regulation of CEBPa and ATF3 [167]. Additionally, we
identified 54 ATF3 downstream target genes that were differentially expressed in the
Trib1Δhep mouse liver and found that these were similarly CEBPa-dependent. Furthermore,
analysis of ChIP-seq for differential CEBPa binding sites in Trib1Δhep mouse livers
confirmed that there is an enrichment in binding motifs for ATF family members, including
ATF3 and its upstream regulator ATF4 in CEBPa bound regions. These results are
consistent with a model in which the deletion of Trib1 allows CEBPa protein to escape
targeted proteolysis (via COP1) resulting in increased CEBPa protein. The increased
CEBPa protein directly interacts with the Atf3 promoter and leads to its transcriptional
upregulation. The ATF3 protein (which CEBPa also binds directly) binds the Ldlr promoter
and represses its activity thereby resulting in the downregulation of LDLR mRNA and
protein.
A recent publication by Xu et al. [175] investigated the effects of hepatocyte ATF3 in the
regulation of bile acids, HDL metabolism and atherosclerosis, and demonstrated that
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hepatocyte ATF3 enhances HDL uptake, inhibits intestinal fat and cholesterol absorption
and promotes macrophage reverse cholesterol transport. Consistent with earlier studies,
they found that the mechanism by which ATF3 regulates these is by inducing scavenger
receptor group B type 1 (SR-BI) and repressing cholesterol 12α-hydroxylase (CYP8B1) in
the liver through its interaction with p53 and HNF4A [175]. Additionally they explored the
effects of hepatic Atf3 on the Ldlr and showed that that ATF3 upregulates hepatic
expression and protein levels of LDLR in mice [175]. Strikingly, the direction of effect of
ATF3 on LDLR in Xu et al. is opposite to the previously published results by Lim et al
[164], from which we based our hypothesis. We speculate that this may be because in our
Trib1Δhep mice, levels of both ATF3 and CEBPa are elevated and that the concomitant
elevation of CEBPA may change the nature of the effects of ATF3 on Ldlr transcription.
To further test our model, we acquired an siRNA directed against mouse Atf3 and a nontargeting control siRNA with the hypothesis that preventing ATF3 upregulation in Trib1Δhep
mice would impact LDLR protein and plasma cholesterol levels. We injected Trib1Δhep
mice with siRNAs to Atf3 or luciferase and control mice with siRNA to luciferase. Using
this method, we were able to attenuate ATF3 protein levels in mice receiving Atf3 siRNA
to levels comparable to control mice. This normalization of ATF3 was associated with a
significant reduction in plasma levels of total cholesterol and in HDL cholesterol, but had
no effects on triglycerides and non-HDL cholesterol. The decrease in ATF3 protein was
also associated with modestly increased levels of LDLR protein compared to mice injected
with control siRNA. This result supports the model that ATF3 contributes to the downregulation of LDLR in Trib1Δhep mice. Based on these results and our current findings we
conclude that increased Atf3 expression in the livers of Trib1Δhep mice is leading to the
partial down regulation of the Ldlr expression in a sterol-independent mechanism.
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However, it is important to note that the decrease in lipids and increase in LDLR protein
in Trib1Δhep mice treated with Atf3 siRNA were only partially attenuated, suggesting that
ATF3 is not the only partner contributing to Trib1 and CEBPa effects on lipids. It is very
likely that other factors are also involved in this regulation.
In summary, our experiments show that deletion of hepatic Trib1 regulates plasma LDLC levels by resulting in downregulation of the expression of the Ldlr and consequently the
rate of LDL-apoB clearance. Trib1 mediates these effects through its post-translational
regulation of CEBPa protein degradation. We also identified atf3 as at least one
mechanism by which Trib1 and CEBPa regulate Ldlr expression. This study provides new
functional insight into the strong genetic association between TRIB1 and LDL-C levels.
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FIGURES

Figure 4. 1: CebpaΔhep model validation.
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Figure 4.1: A. Hepatic transcript levels of Trib1 and Cebpa in chow-fed mice (n=5) 10
weeks after AAV-Cre injection. Box plots indicate median, 25th and 75th percentiles with
whiskers extending to minimum and maximum values. Symbols indicate single values.
Significance was determined by Two-way ANOVA with Tukey’s multiple correction test
(****p ≤ 0.0001). B. Hepatic protein levels of CEBPα and Actin in mice (n=2 per group),
from A.
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Figure 4. 2: Hepatic deletion of Trib1 in the absence of Cebpa decreases plasma
cholesterol in chow and WTD feeding.
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Figure 4.2: A-D. Plasma levels of triglycerides, total cholesterol, HDL cholesterol and nonHDL cholesterol in chow-fed male mice 4 weeks after AAV injection (n=5-6). E-H. Plasma
levels of triglycerides, total cholesterol, HDL cholesterol and non-HDL cholesterol in WTD
feed mice for 6 weeks (n=8-9). Box plots indicate median, 25th and 75th percentiles with
whiskers extending to minimum and maximum values. Symbols indicate single values.
Significance was determined by One-way ANOVA with Tukey’s multiple correction test (*p
≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001).
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Figure 4. 3: Hepatic deletion of Trib1 in the absence of Cebpa decreases LDL
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Figure 4.3: A-B. Fast Protein Liquid Chromatography (FPLC) was performed on pooled
plasma from chow fed mice for 6 weeks and C-D. WTD fed mice for 14 weeks to separate
lipoproteins based on their size. Triglycerides (A, C) and total cholesterol (B, D)
concentrations were measured in all fractions.
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Figure 4. 4: Hepatic deletion of Trib1 in the absence of Cebpa normalizes hepatic
lipids, ALT and albumin levels.
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Figure 4.4: A-B. Hepatic triglyceride and total cholesterol levels in chow fed mice 8 weeks
post deletion (n=5). C. ALT levels at indicated timepoints over 4 weeks of chow feeding
(n=5). D. Plasma Albumin levels in chow fed mice 4 weeks post deletion (n=5). A, B, D.
Box plots indicate median, 25th and 75th percentiles with whiskers extending to minimum
and maximum values. Symbols indicate single values. Significance was determined by
One-way ANOVA with Tukey’s multiple correction test. C. Data are expressed as mean ±
s.e.m for the experimental group. Significance was determined by Two-way ANOVA with
Tukey’s multiple correction test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001).
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Figure 4. 5: Hepatic deletion of Trib1 in the absence of Cebpa improves postprandial triglyceride clearance in mice.
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Figure 4.5: A. Oral fat tolerance test (OFTT) in male mice at 5 in chow diet. Data are
expressed as mean ± s.e.m for the experimental group. B.

Area under the curve

calculation for A. Data are expressed as mean ± s.e.m for the experimental group.
Significance was determined using one-way ANOVA with Tukey’s multiple comparisons
test (**p≤0.01, ***p≤0.001)
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Figure 4. 6: Hepatic deletion of Trib1 in the absence of Cebpa normalizes LDL and
VLDL apoB kinetics and LDLR expression.
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Figure 4.6: A-B. 125I-LDL-apoB clearance and FCR in chow-fed male mice 8 weeks after
AAV injection (n=5). C-D.

125

I-VLDL-apoB clearance and FCR in chow-fed male mice 8

weeks after AAV injection. E. Hepatic transcript levels of Ldlr in mice 8 weeks after AAV
injection (n=5), F. Representative immunoblot of hepatic LDLR and β-actin from samples
in E. A, C. Data are expressed as mean ± s.e.m for the experimental group. B, D, E. Box
plots indicate median, 25th and 75th percentiles with whiskers extending to minimum and
maximum values. Symbols indicate single values. Significance was determined by oneway ANOVA with Tukey’s multiple comparison test (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001,
****p ≤ 0.0001).
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Figure 4. 7: Summary of differentially expressed genes between different groups
from RNAseq dataset.

Figure 4.7: Volcano plots representing the totality of differentially expressed genes in
Trib1Δhep compared to control mice (A), in Trib1Δhep;CebpaΔhep compared to control mice
(B), in Trib1Δhep;CebpaΔhep compared to Trib1Δhep mice (C), in CebpaΔhep as compared to
control mice (D) and in Trib1Δhep;CebpaΔhep compared to CebpaΔhep mice (E). Analysis
was performed in chow fed mice 4 weeks after AAV-CRE injection (n=6). Dashed
horizontal line -log10(adjusted p-value = 0.00001), dashed vertical lines indicate
absolute log2 fold-change relative to control =0.6 (equivalent to ±1.5x). Grey squares,
non-significant; blue circles, significant for comparison between Trib1Δhep and control;
orange triangles, significant for comparison between Trib1Δhep and control, but not for
Trib1Δhep;CebpaΔhep compared to control.
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Figure 4. 8: Zoomed in versions of selected volcano plots of differentially
expressed genes in RNAseq dataset.

Figure 4.8: A. Cropped volcano plot of differentially expressed genes in Trib1Δhep
compared to control mice. B. Cropped volcano plot of differentially expressed genes n
Trib1Δhep;CebpaΔhep compared to control mice. Analysis was performed in chow fed mice
4 weeks after AAV-CRE injection (n=6). These plots represent the same data as that in
Fig. S10A and B, zoomed in for additional detail. Dashed horizontal line -log10(adjusted
p-value =0.00001), dashed vertical lines indicate absolute log2 fold-change relative to
control =0.6 (equivalent to ±1.5x). Grey squares, non-significant; blue circles, significant
for comparison between Trib1Δhep and control; orange triangles, significant for comparison
between Trib1Δhep and control, but not for Trib1Δhep;CebpaΔhep compared to control.
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Figure 4. 9: Ingenuity Pathway Analysis plots representing the changes in LDLR
upstream regulators between different groups

Figure 4.9: Ingenuity pathway analysis of all predicted liver-expressed ligand-dependent
nuclear receptors, transcription factors, and transcriptional regulators upstream of Ldlr
(based on IPA knowledge base) overlaid with color-coded mouse liver RNAseq from the
comparisons listed above each plot. Analysis was performed in chow fed mice 4 weeks
after AAV-CRE injection (n=6). DKO=Trib1Δhep;CebpaΔhep. Red= upregulated genes, Blue=
downregulated genes.
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Figure 4. 10: Effects of hepatic deletion of Trib1 and Cebpa on SREBP family
members.
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Figure 4.10: A-B. Hepatic Srebf1 mRNA and SREBP1 protein levels in chow fed mice 4
weeks after AAV8-CRE injection. C-D. Hepatic Srebf2 mRNA and SREBP2 protein levels
in chow fed mice 4 weeks after AAV8-CRE injection. P, preprotein; M, mature protein. Box
plots indicate median, 25th and 75th percentiles with whiskers extending to minimum and
maximum values. Symbols indicate single values. Significance was determined by oneway ANOVA with Tukey’s multiple comparison test (***p ≤ 0.001, ****p ≤ 0.0001).
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Figure 4. 11: Hepatic deletion of Trib1 increases Atf3 mRNA and protein levels in a
CEBPA dependent manner
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Figure 4.11: A. Hepatic transcript levels of ATF3 in chow-fed male mice (n=6 per group)
4 weeks after injection AAV-CRE. B. Immunoblot of hepatic ATF3 and β-actin, replicated
in 3 independent cohorts. Box plots indicate median, 25th and 75th percentiles with
whiskers extending to minimum and maximum values. Symbols indicate single values.
Significance was determined by one-way ANOVA with Tukey’s multiple comparison test
(****p ≤ 0.0001).
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Figure 4. 12: Ingenuity pathways analysis plot of Atf3 downstream regulated
factors in RNAseq cohort samples

Figure 4.12: Ingenuity pathways analysis plot of Atf3 downstream regulated factors in
RNAseq cohort samples comparing Trib1Δhep mice to control mice (A), Trib1Δhep :
CebpaΔhep mice to control mice (B), Trib1Δhep;CebpaΔhep compared to Trib1Δhep mice (C),
CebpaΔhep as compared to control mice and (D) and Trib1Δhep;CebpaΔhep as compared to
CebpaΔhep mice (E). Color overlays reflect the ratio of the differentially expressed
transcript: for example, Cepbe is up-regulated (red), and Cebpa down-regulated (deleted,
blue) in Trib1Δhep;CebpaΔhep compared to Trib1Δhep (leftmost figure). Analysis was
performed in chow fed mice 4 weeks after AAV8-CRE injection (n=6).
98

B
✱✱✱✱

1.5

Atf3 Normalized Expression

A

Trib1 Normalized Expression

Figure 4. 13: Atf3 siRNA deletion efficiency.
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Figure 4.13: A-B. Hepatic transcript levels of Trib1 and Atf3 in 7 controls, 4 Trib1Δhep
Luciferase and 4 Trib1Δhep Atf3 siRNA. C. Immunoblot of hepatic ATF3 and β-actin. Box
plots indicate median, 25th and 75th percentiles with whiskers extending to minimum and
maximum values. Symbols indicate single values. Significance was determined by oneway ANOVA with Tukey’s multiple comparison test (**p ≤ 0.01, ***p ≤ 0.001, ****p ≤
0.0001).
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Figure 4. 14: Downregulation of Atf3 in Trib1Δhep mice reduces total cholesterol
and HDL-C
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Figure 4.14: A, E, I, M. Total cholesterol, HDL cholesterol, non HDL cholesterol and
triglycerides in control and Trib1Δhep 2 weeks after AAV injection and prior to siRNA
treatment (n=7 each). B, F, J, N. Total cholesterol, HDL cholesterol, non HDL cholesterol
and triglycerides prior to siRNA treatment in Trib1Δhep mice divided by eventual siRNA
group (3 Trib1Δhep; siCtrl and 4 Trib1Δhep; siAtf3). C, G, K, O. Time course of plasma total
cholesterol, HDL cholesterol, non HDL cholesterol and triglycerides in siRNA injected
mice. D, H, L, P. Area under the curve of the siRNA treatment time course in panela C,
100

G, K, O; y-axis, arbitrary units. Box plots indicate median, 25th and 75th percentiles with
whiskers extending to minimum and maximum values. Symbols indicate individual values.
Data are expressed as mean ± s.e.m for the experimental group. Significance was
determined by two-tailed, unpaired t-test and by one-way ANOVA with Tukey’s multiple
comparison test (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001).
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Figure 4. 15: Effects of downregulation of Atf3 in Trib1Δhep mice on lipoprotein
distribution.
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Figure 4.15: A. Total cholesterol distribution in FPLC-fractionated from day 30 pooled
plasma. B-C. Zoomed in plots of A. E. Triglyceride distribution in FPLC-fractionated from
day 30 pooled plasma. F-G. zoomed in plots of E.
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Figure 4. 16: Downregulation of Atf3 in Trib1Δhep mice increases LDLR protein
levels.
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Figure 4.16: A. Hepatic transcript levels of Ldlr in 7 controls, 4 Trib1Δhep Luciferase and
4 Trib1Δhep Atf3 siRNA. B. Immunoblot of hepatic LDLR and β-actin. Box plots indicate
median, 25th and 75th percentiles with whiskers extending to minimum and maximum
values. Symbols indicate single values. Significance was determined by one-way ANOVA
with Tukey’s multiple comparison test.
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Figure 4. 17: Proposed mechanistic model of how Trib1 regulates the LDLR in a
CEBPa dependent manner.

Figure 4.17: Our results are consistent with a model in which the hepatic deletion of Trib1
allows CEBPa protein to escape targeted proteolysis, resulting in increased CEBPa
protein. The increased CEBPa protein directly interacts with the Atf3 promoter and leads
to its transcriptional upregulation. The ATF3 protein (which CEBPa also binds directly)
binds the Ldlr promoter and represses its transcription thereby resulting in the
downregulation of LDLR mRNA and consequently of LDLR protein.
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Table 2. Motif enrichment analysis of CEPBA ChIP-seq in liver from Trib1Δhep mice.
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CHAPTER 5:
Constitutive deletion of Trib1 in mice leads to highly penetrant neonatal lethality
due to impaired glucose metabolism.

ABSTRACT
The effects of hepatic TRIB1 on plasma lipid metabolism have been broadly studied,
however not a lot of work has been done in determining the effects of extra-hepatic TRIB1
on plasma lipids and other metabolic traits. To explore the extra-hepatic effects of TRIB1’s
on lipid metabolism we acquired a mice line homozygous for Trib1 whole body deletion
(Trib1 KO) on a pure C57BL/6 background, however we found that this model presented
a highly penetrant lethal phenotype of unknown etiology. The goal of these studies was to
determine the developmental stage at which lethality was occurring, as well as to
determine the physiological mechanism leading to the lethal phenotype. Our studies
determined that Trib1 KO mice develop normally in uterus and that the period of lethality
was post-natal, between day 0 and day 1 after birth. We hypothesized that this was likely
due to severely low blood glucose levels compared to control mice. We also determined
that about 5% of Trib1 KO mouse survive the neonatal lethally period and make it to
adulthood and that similar to Trib1Δhep mice, Trib1 KO have increased plasma lipids and
impaired postprandial lipemia. I also demonstrated that Trib1 KO mice have decreased
fasting glucose levels, and that their glucose and insulin tolerance is improved compared
to wild type and heterozygous mice. Trib1Δhep mice also had improved glucose tolerance
with no changes in insulin tolerance. The results from these studies suggest that additional
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to regulating plasma lipids, Trib1 is involved in the regulation of glucose metabolism, an
association that has not been previously reported. However, questions regarding which
tissues and the specific molecular mechanism by which Trib1 regulates glucose
phenotypes in mice remain unanswered.
INTRODUCTION

To explore the extra-hepatic effects of TRIB1’s on lipid metabolism we acquired a mice
line homozygous for Trib1 whole body deletion (Trib1 KO) on a pure C57BL/6 background,
however we found that this model presented a highly penetrant lethal phenotype of
unknown etiology. Based on this finding, we sought to investigate at which stages of
development was the lethality occurring, as well as which physiological mechanism was
impaired in these mice causing lethality.
The mouse is the most used model to study the genetic effects of mammalian gene
mutation on biological function, however, it presents certain challenges that make their
study difficult. One of the main challenges is that many mutations produced through
genetic engineering can affect the developmental processes of the mutant embryos and
compromise their survival rates [178]. Additional to affecting embryonic and fetal
development, some mutations also intervene with survival at neonatal stages [179], which
represents a limitation for understanding the physiological effects to certain genetic
mutations in mice.
The lethality phenotypes at each stage of development are characterized by different
physiological manifestations. At the embryonic/fetal state lethality can occur at early
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stages of fertilization or implantation, or later stages of development [178]. Appropriate
development through implantation depends on the development of extraembryonic tissues
like the trophoblast, a layer of tissue on the outside of a mammalian blastula, which
supplies the embryo with nourishment [180-182]. The process of gastrulation if also very
crucial in these early stages, which will result in the formation of the primary germ layers
and extraembryonic structures that will contribute to the yolk sac and the placenta [180182]. Neural, lung, cardiovascular and renal development occur to fulfill appropriate
development these tissues and organs that are required for life, and mutations or
physiological deformities that affect any of these systems have been associated with
deathly phenotypes in mice [178].
If the mice form normally and make it through the whole term, then it must overcome the
process of parturition which is highly stressful for newborn pups. During gestation, the
fetus depends on the placenta to supply nutrients, metabolic exchange and waste
disposal; and glucose is the main energy source for fetal development [183, 184]. This
stage of development for the fetus is characterized by high plasma insulin and low plasma
glucagon levels [185, 186]. High levels of insulin signals to the liver that blood glucose is
high, which causes tissues to absorb glucose and store it as glycogen, the primary
carbohydrate stored in the liver and muscle cells of animals [187-190]. When blood sugar
levels drop, glucagon signals the liver to break down glycogen into glucose, a process
called glycogenolysis, causing blood sugar levels to increase [191]. Before birth, the
expression of hepatic glycogen synthase is increased to promote tissue glycogen storage
to endure the postnatal survival of the newborn [127, 192].
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Soon after birth, the mice go through a period of starvation that is associated with the
abrupt cessation of maternal nutrient supply previously provided through the umbilical
cord, and neonatal metabolism must adapt to survive [193, 194]. In these early stages of
life, glucose is still one of the most important sources of energy for the brain and vital
organs, and the body undergoes many metabolic and hormonal changes to stabilize
glucose levels [193]. The period right after birth and before suckling is characterized by
an increase in glucagon and glucagon receptors and a decrease of insulin levels [179,
193]. This low insulin/high glucagon molar ratio is essential to produce glucose through
glycogenolysis and gluconeogenesis, the latter which is metabolic pathway that results in
the generation of glucose from non-carbohydrate carbon substrates [195]. In humans the
main gluconeogenic precursors are lactate, glycerol, alanine and glutamine, which
account for ~90% of gluconeogenic substrates [191]. The early postnatal stage is also
characterized by an increased in glucocorticoids, which together with the increase in
glucagon and catecholamine, promotes lipolysis and muscle protein breakdown, which
increases the availability of gluconeogenic substrates [195]. Also, an increase in long
chain fatty acid oxidation and ketone body production during the first 24 h following birth
has been reported to contribute as alternative fuels to spare glucose requirements of
neonates [196].

Any mutations that disrupt glucose homeostasis or the normal

development of the liver or pancreas (which is crucial for the production of insulin) are
associated with an array of developmental diseases and death due to their possible effects
on energy balance.
Neonatal lethality due to hypoglycemia has been studied in several mouse models and
has been associated with multiple physiological mechanism [127, 197-201]. Following
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birth neonates go throw transient hypoglycemia until glycogenolysis and gluconeogenesis
are activated in the liver, but improper activation of any of these pathways could lead to
severe hypoglycemia and neonatal lethality. It has also been shown that autophagy is a
critical source of energy in these early stages of life, which is induced in response to
starvation within 3-6 hours after birth [200]. This was confirmed in Atg5 KO an Atg7 KO
mice, in which autophagosome fusion is blocked, and these mice die within 12 hours of
birth with their energy levels depleted [200]. Another gene studied for it effect in neonatal
lethality is CEBPa, which is a gene highlighted in my research. Cebpa mutant neonates
show reduced glucose levels and die within 8 hours of birth due to their inability to store
glycogen in the liver prior to birth and exhibited a remarked lack of lipids in their
hepatocytes and adipocytes [127]. Neonatal hypoglycemia can also result from increased
insulin sensitivity, and it is associated with cyanosis and lethargy in mice with mutations
in the Ship2/phx2a loci [197]. Other causes for neonatal hypoglycemia can be associated
with respiratory distress and abnormal feeding [179].
The results from our studies suggest that the lethal phenotype in Trib1 KO mice occurs
postnatally due to severe hypoglycemia, and that the small percentage of Trib1 KO mice
that survives postnatal lethality (~5% survival rate) also present phenotypes of reduced
glucose levels due to improved glucose tolerance and higher insulin sensitivity. The TRIB1
gene has been broadly associated with multiple cardiometabolic traits, however glucose
metabolism is not one of them. The results from these studies suggest a novel
physiological association with TRIB1 and glucose regulation mice, however questions
regarding the molecular mechanism by which Trib1 regulates glucose phenotypes in mice
remain unanswered.
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RESULTS

Trib1 KO mice have normal embryonic development but die postnatally.
In order to study the extra-hepatic effects of Trib1 on plasma lipid metabolism, we acquired
a mice line homozygous for Trib1 whole body deletion (Trib1 KO) on a pure C57BL/6
background, however we found that this model presented a highly penetrant lethal
phenotype of unknown etiology. Previous unpublished studies from Rob Bauer in our lab
focused in determining the developmental stage at which Trib1 whole body deletion leads
to lethality. Death due to genetic mutations can occur at different developmental stages,
during fetal development (fetal death), within one day after birth (neonatal death) or after
the first day of birth (postnatal death). Dr. Bauer previously studied several stages of
embryonic development and was able to find that Trib1 KO mice are present at every
stage in utero, and they had no differences in gross appearance or any visible
morphological defects. These mice also had normal development of cardiovascular and
pulmonary systems compared to control mice. These data suggested that Trib1 KO mice
have normal embryonic development and perish on their neonatal or postnatal period after
birth. The mice were followed after birth, and we were able to determined that the time of
death ranges between neonatal day 0 and neonatal day 1. Trib1 KO mice were born in a
normal Mendelian ratio, showed no visual developmental deformities and nursed at
normal rates compared to wild type mice, however they rarely survive to adult stages
(weaning at 4 weeks).

These observations led us to further hypothesis that the

physiological mechanism leading to neonatal death is due to a metabolic disorder, likely
due to improper adaptation to new metabolic needs after birth.
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Trib1 KO neonate mice have severe hypoglycemia.
As discussed earlier, glucose is one of the most important sources of energy for early
neonates and regulating glucose levels is crucial to ensure survival. To determine if Trib1
KO mice have impaired glucose levels at early stages of life, mice were collected right
after birth to collect blood and tissues. I measure glucose levels in all mice at the moment
of death and discovered that Trib1 KO mice have striking low levels of glucose compared
to wild type mice (Figure 5.1). Trib1 heterozygous mice presented intermedium glucose
levels between wild type and KO mice (Figure 5.1), suggesting that the effect of Trib1 on
glucose levels is gene-dose dependent. Based on how important glucose homeostasis is
for survival, we strongly believe that severe hypoglycemia is the cause of death on Trib1
KO mice. Regulation of insulin levels in the circulation is crucial to maintain euglycemia;
and concentration in the plasma is largely determined by the rate of secretion from beta
cells in the pancreas [202]. Failure to regulate insulin production and secretion or insulin
clearance can result in increased plasma insulin levels, which could lead to the
hypoglycemic phenotype in Trib1 KO mice. We tried measuring insulin levels in Trib1 KO
mice compared to wild type and heterozygous mice, however insulin levels were
undetected in all the groups. It is possible that at this early-stage of development insulin
levels are too low in these mice to be detected, for which reason it couldn’t be detected
by our assay.

Trib1 KO neonate mice have normal liver lipids and ketones but decreased lactate
and glycogen levels.
As Trib1 is known for its effects on hepatic lipid metabolism, we decided to explore hepatic
levels of triglycerides and cholesterol and saw no differences between the groups (Figure
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5.2 A-B), suggesting that hepatic lipid levels are not contributing to the metabolic effects
observed in Trib1 KO mice. Ketone body production is known to increase substantially
during the first 24 h following birth and to contribute as fuel for glucose requirements on
neonates, however, no differences were observed between the groups (Figure 5.2 C).
Lactate, which is a key substrate for gluconeogenesis, was significantly decreased in a
dose dependent manner on Trib1 Het and Trib1 KO mice (Figure 5.2 D). Additionally,
glycogen, which is highly important for glucose production in early neonates, was strikingly
reduced in both Trib1 Het and Trib1 KO mice, however not in a dose dependent manner
(Figure 5.2 E). The decrease in ketones and glycogen can both be causing or contributing
to the hypoglycemic phenotype in Trib1 KO mice, however more experiments are needed
to determine the exact mechanism leading to neonatal hypoglycemia and death.

Trib1 KO neonate mice have increased levels of lipogenic genes.
As Trib1 is known for its effects on lipogenic gene expression, we decided to explore for
changes in expression in some target genes. First, we were able to confirm complete
knockout of Trib1 in Trib1 KO mice, as well as intermedium knockout in Trib1 het mice
(Figure 5.3 A). We also observed a significant reduction on Cebpa mRNA levels (Figure
5.3 B), like what has been shown in Trib1Δhep mice. I observed an increase in the
expression of Fatty Acid Synthase (Fasn) and Acetyl-CoA Carboxylase Alpha (ACACA)
(Figure 5.3 C-D), both genes which are involved in the synthesis of fatty acids. These data
show that even at this young age, Trib1 KO mice present similar gene expression to
Trib1Δhep mice. Even though the increased of these genes is associated with increased
hepatic lipids in Trib1Δhep mice, this phenotype is not recapitulated right after birth in
neonates.
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Trib1 KO neonate mice have normal levels of glucogenic genes.
As Trib1 KO mice suffer from severe hypoglycemia, we decided to explore if there were
any changes in expression on genes associated with the process of glucose production in
the liver. I explore for changes in Phosphoenolpyruvate carboxykinase (PEPCK), which
encodes an enzyme that catalyzes the rate-limiting step of gluconeogenesis; Glucose-6phosphatase catalytic subunit (G6pc), which encodes a key enzyme in glucose
homeostasis which functions in gluconeogenesis and glycogenolysis; and Glycogen
synthase 1 (Gys1), which encodes a key enzyme for glycogen production [191]. However,
no changes in mRNA expression were observed in any of these genes when comparing
Trib1 KO to control mice (Figure 5.4).

Adult Trib1 KO mice have increased plasma lipids and impaired postprandial
triglyceride clearance.
In my time breeding these mice we have found out that about 5% of Trib1 KO mice are
able to survive the neonatal lethally period and make it to adulthood. I studied 3 surviving
Trib1 KO together with wild type and heterozygous adult age matched mice and
phenotype them for changes in plasma lipid metabolism. Trib1 KO mice presented with
low triglyceride levels, increased total cholesterol, no changes in HDL cholesterol and
increased non-HDL cholesterol and plasma ALTs (Figure 5.5). Trib1 KO mice also
presented highly impaired triglyceride clearance phenotype after a high lipid load (Figure
5.6 A), which was confirmed by calculating the area under the curve (Figure 5.6 B). These
results from adult Trib1 KO mice are similar to what was observed in the Trib1hep mice,
suggesting that hepatic Trib1 is mostly contributing to the plasma lipid metabolism
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phenotypes observed. More interestingly, Trib1 Het mice did not show differences in
plasma lipids or postprandial lipemia compared to control, suggesting that 50% expression
of Trib1 is sufficient to maintain a normal plasma lipid phenotype in these mice.

Adult Trib1 KO mice have reduced glucose, increased lactate, and normal ketone
plasma levels.
As Trib1 KO neonate mice die from severe hypoglycemia, we decided to explore if the
surviving adult Trib1 KO mice have any impairment in glucose metabolism. We measured
glucose levels at different fed and fasted times in mice and showed that fed Trib1 KO mice
have normal glucose levels compared to wild type and heterozygous mice, however, short
time fasting of 4 and 6 hours significantly reduces glucose levels in Trib1 KO mice and
that in overnight fasted Trib1 KO mice glucose levels are back to normal (Figure 5.7 A).
Overall, all groups presented a reduction in glucose overtime, this likely due to the lack of
nutrient uptake. These results suggest that similar to neonate mice, adult Trib1 KO mice
have an impaired regulation of glucose levels. We also explore for changes in lactate
levels and observed that Trib1 KO mice have normal levels at fed and 4-hour fasting, but
that lactate levels are significantly increased after overnight fasting (Figure 5.7 B). Ketones
levels in Trib1 KO mice were comparable to control and Trib1 Het mice, however overnight
fasting strikingly increased ketone levels in all groups, this likely due to the low levels of
glucose which induce fatty acid breakdown and ketone body formation as an alternative
source of energy.
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Adult Trib1 KO mice have improved glucose and insulin tolerance, and Adult
Trib1Δhep mice have improved glucose tolerance with no changes in insulin
tolerance.
Increased plasma and hepatic lipids are usually associated with defects in glucose
tolerance and insulin sensitivity in mammals. I performed glucose tolerance test (GTT)
and insulin tolerance test (ITT) in this cohort to determine if there were any defects in Trib1
KO mice. Surprisingly, Trib1 KO mice have improved glucose clearance after glucose or
insulin bolus infusions, which means they have improved insulin sensitivity to glucose
(Figure 5.8). These studies were performed in Trib1hep mice, which showed improved
glucose sensitivity, but no changes in insulin sensitivity (Figure 5.9). These results suggest
that Trib1 effects on insulin sensitivity to glucose are mediated by extra-hepatic tissues,
with the pancreas being the most obvious target as it regulates the production and
secretion of insulin. It was surprising to see that even though these mice have increased
lipids, which in human usually leads to insulin resistance and diabetes, both Trib1 KO and
Trib1hep mice have improved glucose sensitivity. It would be interesting to further study the
mechanisms that lead to these phenotypes. Overall, the findings from these studies further
solidify our hypothesis that Trib1 is associated with the regulation of glucose metabolism
both in early stages of development and in adulthood in mice.

Adult Trib1 het and KO mice have similar mRNA expression pattern as Trib1Δhep
mice.
Even though they survive neonatal lethality due to hypoglycemia, adult Trib1 KO mice
have higher mortality rates associated with the development of prolapse rectum. From the
cohort I followed, 2 out of 3 Trib1 KO mice developed prolapsed rectum and die because
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of it. From previous cohort with sporadic surviving Trib1 KO mice, the development of
prolapsed rectum was observed often, but not quantified. For this reason, they needed to
be euthanized at an earlier age, which made it challenging to matched them to control and
het mice for long term experiment and collect tissues for mRNA and protein studies. I
collected tissue from 1 surviving Trib1 KO mouse and compared it to its match wild type
and het mice. Overall, Trib1 KO mice showed a trend of hepatic mRNA expression very
similar to Trib1Δhep mice. Trib1 expression was undetected and Cebpa expression was
reduced to about 50% of wild type mice. Trib1 KO mice showed increased expression of
lipogenic gens such as Dgat2, Fasn and Acaca (Figure 5.10). There were no differences
in Ldlr expression but increased Atf3 expression (Figure 5.10). The results from these
studies are interesting, however limited interpretation can be done as it is based on only
one Trib1 KO mouse. It will be necessary to further breed these mice to obtain more Trib1
KO mice for analysis of hepatic and extra-hepatic gene expression of genes associated
with glucose and plasma lipid metabolism.
DISCUSSION

The TRIB1 gene, which encodes Tribbles homolog 1 protein (TRIB1), has been suggested
as causal for the highly robust genome-wide association study (GWAS) signal at human
chromosomal locus 8q24 for a remarkable number of cardiometabolic traits, including
plasma lipids and lipoproteins, hepatic steatosis, adiponectin levels, and coronary artery
disease [69, 124, 146, 148]. However, no previous association with glucose metabolism
has been described.
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In our studies we explore Trib1 whole body deletion effect on the pure C57BL/6
background mice, as this background is the most used to study metabolic traits in mice.
However, we demonstrated that Trib1 whole body deletion in this background leads to a
highly penetrant neonatal lethality, with only about 5% of Trib1 KO mice making it to adult
stages. Other models of whole body Trib1 deletion on mixed backgrounds have been
used, and even though they are viable, unofficial reports of decreased survival have been
cited and not fully described. We show that Trib1 KO mice die at neonatal stages, which
usually is associated with defects in adjusting to new metabolic needs after birth.
Soon after birth, mammals go through a period of starvation that is associated with the
abrupt cessation of maternal nutrient supply and adaptation to new metabolic needs to
regulate their own homeostasis [186, 193]. In these early stages of life, glucose is one of
the most important sources of energy for the brain and vital organs and the body
undergoes many metabolic and hormonal changes to stabilize glucose levels. Before birth,
glycogen synthase expression is increased in the liver to promote glycogen storage that
will allow survival of the newborn during postnatal starvation [192]. The period right after
birth is characterized by an increase in glucagon and a decreased in insulin levels, which
induces hepatic glycogenolysis and gluconeogenesis to produce glucose from the stored
glycogen and other non-carbohydrate carbon substrates, respectively [185, 186, 191-193,
195, 196].
Our studies show that Trib1 KO mice have significantly low levels of glucose compared to
control mice, and that Trib1 Het mice have an intermedium phenotype between KO and
wild type mice. We decided to measure insulin levels in these mice, as insulin is highly
important in the regulation of glucose, and low levels are necessary to promote survival at
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this early stage. However, our assay was unable to detect plasma insulin in any of the
mice. It is possible that the stage at which the mice are collected plasma insulin levels are
too low to be detected. Due to the limited amount of plasma collected from these mice,
this test was performed only once on pooled plasma from several mice, and the plasma
was thawed twice. It is possible that the already low levels of insulin quickly degraded after
being collected and processed. Either way, this test needs to be repeated with fresh
samples to confirm this result.
Additional to having severely low glucose levels, Trib1 KO neonates also had significantly
low levels of lactate, with Trib1 Het mice presenting an intermedium phenotype between
Trib1 KO and wild type mice, a similar trend to the one observed for glucose. Lactate
serves as a precursor for gluconeogenesis in the liver, which induces the production of
glucose [195]. Low levels of lactate could result in decreased gluconeogenesis and
decreased glucose levels in mice, which could be causing the severe hypoglycemia in
Trib1 KO mice. Additional to low lactate levels, Trib1 KO mice also have significantly low
levels of hepatic glycogen, which is crucial to maintain euglycemia at these early stages.
Because Trib1 Het mice also have low levels of glycogen comparable to Trib1 KO mice,
we don’t think that this alone could be causing neonatal lethality. However, the decreased
in both lactate and glycogen in Trib1 KO mice could be causing or strongly contributing to
the severe hypoglycemic phenotype in these mice. Replicating these finding in a bigger
cohort is necessary to corroborate these results. Additionally, glycogen staining in the
livers of these mice should be performed, as it is a more reliable measurement for
glycogen levels.
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Further, we decided to explore if there were any changes in expression on certain genes
associated with the process of glucose production. We looked for changes in Pepck, G6pc
and Gys1 and observed no differences on the mRNA of these genes that are involved in
the processes of gluconeogenesis and glycogenolysis. However, it is possible that the
phenotypes in Trib1 KO mice are regulating by other genes. A better approach to identify
candidate genes regulating Trib1 KO glucose phenotypes would be to perform unbiased
RNA sequencing in the liver and pancreas of these mice, which are two of the most
important tissues regulating glucose metabolism. The results from the RNA sequencing
would provide with an array of candidates to study for this purpose. Our studies suggest
that severe hypoglycemia in Trib1 KO neonates is caused by decreased levels of lactate
and glycogen, however, more studies are necessary to confirm this as well as to determine
the molecular mechanism leading to these phenotypes.
While breeding Trib1 KO mice we discovered that about 5% of Trib1 KO mouse survive
the neonatal lethally period and make it to adulthood. I studied these mice together with
wild type and heterozygous adult mice and determined that like Trib1hep mice, they have
increased plasma lipids and impaired postprandial lipemia, which suggested that hepatic
Trib1 is solely responsible for the regulation of plasma lipids in these mice. I also
demonstrated that Trib1 KO mice have decreased glucose levels during short time fasting
and that they have improved glucose and insulin tolerance compared to Trib1 wild type
and heterozygous mice. I also demonstrated that Trib1hep mice also had improved glucose
tolerance with no changes in insulin tolerance, suggesting that Trib1 effect on insulin
response is mediated by extra-hepatic tissues. A possible candidate tissue will be the
pancreas, as it is the main tissue regulating the production and secretion of insulin. These
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results confirmed our hypothesis that additional to regulating lipid metabolism, Trib1
serves a regulator of glucose metabolism in mice, an association that had not previously
been described or tested. However, Additional studies to determine the molecular
mechanism leading to trib1 regulation of glucose levels are necessary to fully understand
these phenotypes.
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FIGURES

Figure 5. 1: Trib1 KO neonate mice have decreased plasma glucose levels.
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Figure 5.1: Plasma glucose levels were measure at postnatal day 0 in several cohort of
mice (n= 20 controls, 54 HET and 14 KO). Data indicate individual values with mean ±
s.e.m. Significance was determined by One-Way ANOVA multiple comparison (**P≤0.01,
****P≤0.0001).
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Figure 5. 2: Trib1 KO mice have normal hepatic lipids and plasma ketones, but
reduced plasma lactate and hepatic glycogen levels.
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Figure 5.2: A-B. Hepatic triglycerides and total cholesterol in neonate mice right after
birth. C. Plasma ketone levels in neonate mice right after birth. D. Plasma lactate levels in
neonate mice right after birth. E. Hepatic levels of glycogen in neonate mice right after
birth. Data indicate individual values with mean ± s.e.m. Significance was determined by
One-Way ANOVA multiple comparison (**P≤0.01, ***P≤0.001).
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Figure 5. 3: Hepatic gene expression of lipogenic genes in neonate mice.
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Figure 5.3: A-D. Hepatic transcript levels of Trib1, Cebppa, FasN and Acaca in Trib1 WT,
HET and KO mice right after birth. Box plots indicate median, 25th and 75th percentiles
with whiskers extending to minimum and maximum values. Symbols indicate single
values. Significance was determined by One-Way ANOVA multiple comparison (*P≤0.05,
****P≤0.0001).
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Figure 5. 4: Hepatic gene expression of glucogenic genes in neonate mice.
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Figure 5.4: A-D. Hepatic transcript levels of Pepck, G6pc and Gys1 in Trib1 WT, HET and
KO mice right after birth. Box plots indicate median, 25th and 75th percentiles with
whiskers extending to minimum and maximum values. Symbols indicate single values.
Significance was determined by One-Way ANOVA multiple comparison (*P≤0.05)
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Figure 5. 5: Adult Trib1 KO mice have increased levels of plasma total cholesterol,
non-HDL cholesterol and ALTS.
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Figure 5.5: A-E.
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Plasma triglycerides, total cholesterol, HDL cholesterol, non-HDL

cholesterol and ALTs in adult Trib1 WT, HET and KO mice after 4 hours fasting. Data
indicate individual values with mean ± s.e.m. Significance was determined by One-Way
ANOVA multiple comparison (*P≤0.05, **≤0.01).
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Figure 5. 6: Adult Trib1 KO mice have impaired postprandial triglyceride
clearance.
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Figure 5.6: A. Oral fat tolerance test in adult Trib1 KO mice after overnight fasting. B.
Area under the curve from A (n=3 WT, 4 HET, 2 KO). Data are expressed as mean ± s.e.m
for the experimental group. Significance was determined by One-Way ANOVA multiple
comparison (*P≤0.05).
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Figure 5. 7: Adult Trib1 KO mice have decreased fasting glucose and increased
fasting lactate, with normal ketone levels.
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Figure 5.7: A-C. Plasma glucose, lactate and ketone levels at indicated fasting time in
adult Trib1 KO mice compared to Trib1 WT and HET mice (n=5 WT, 5 HET, 3 KO). Data
are expressed as mean ± s.e.m for the experimental group. Significance was determined
by Two-Way ANOVA multiple comparison (*P≤0.05, **P≤0.01).
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Figure 5. 8: Adult Trib1 KO mice have improved glucose and insulin tolerance.
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Figure 5.8: A-B. Glucose tolerance test in mice after overnight fasting (n= 4 WT, 4 HET
and 3 KO). C-D. Insulin tolerance test in mice after 6 hours fasting (n= 4 WT, 4 HET and
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Figure 5. 9: Hepatic deletion of Trib1 improves glucose tolerance with no changes
in insulin tolerance.
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Figure 5.9: A-B. Glucose tolerance test in mice after overnight fasting (n= 6 each). C-D.
Insulin tolerance test in mice after 6 hours fasting (n= 6 each). Data are expressed as
mean ± s.e.m for the experimental group. Significance was determined by One-Way
ANOVA multiple comparison (*P≤0.05, ***P≤0.001, ****P≤0.0001).
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Figure 5. 10: Hepatic gene expression in adult Trib1 KO mice.
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Figure 5.10: Hepatic transcript levels of Trib1, Cebpa, Ldlr, Dgat2, FasN, Acaca and Atf3
in adult Trib1 KO mice (n=1), compared to wild type (n=3) and heterozygous mice (n=3).
Data indicate individual values with mean ± s.e.m. Significance was determined by TwoWay ANOVA multiple comparison (*P≤0.05, ***P≤0.001). No statistical significance was
determined on Trib1 KO mouse because of having only one mouse.
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SUMMARY AND FUTURE DIRECTIONS
The goal of this dissertation was to functionally characterize the gene TRIB1, a GWAS
locus that has been broadly associated with multiple cardiometabolic traits such as plasma
triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol and ALTs, as well as
hepatic lipids and the development of hepatic steatosis. Lipids are essential to support life,
as they accomplish a variety of biological functions such as energy storage, phospholipid
bi-layer formation, signaling, and transport [1, 5]. However, their improper metabolism and
accumulation could lead to the development of cardiovascular diseases with high rates of
mortality [28, 85]. For this reason, it is crucial to understand all the genetic players and
mechanisms that regulate plasm lipid metabolism, which could lead to the development
of improved treatments for disease.
The TRIB1 gene was one of the first novel genes identified by GWAS studies to be
involved in the regulation of plasma lipids and cardiovascular disease traits [69, 79]. The
Tribbles gene was originally identified in Drosophila melanogaster as a regulator or cell
division and cell migration, and since its original discovery 3 human homologs has been
described (TRIB1 1-3) [88, 89, 91]. Prior to GWAS association of TRIB1 with plasma lipid
metabolism, most of the studies for this family members were aimed to determine their
function on myeloid cell development through the interactions of their C terminal binding
domains (COP1 and MEK1) with other proteins such as CEBPa, which has shown that
these proteins serve as signal transduction modulators and to target other proteins for
degradation and proteasomal degradation [92, 93, 100-102, 112, 203].
Previous work from our laboratory was focused on validating the TRIB1 association with
plasma lipids, as well as investigating possible mechanism of action using different mouse
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models. Our group was the first one to determine that Trib1 overexpression in mice
reduces plasma lipids, hepatic de novo lipogeneses and VLDL secretion and conversely,
Trib1 hepatic deletion in mice increases plasma lipids, hepatic fat and de novo lipogenesis
[104, 125]. It was also demonstrated that Trib1 effect on hepatic lipogenesis and hepatic
lipids was mediate through an increase in CEBPa protein [104], however CEBPa
involvement in regulating plasma lipids was not explored. Additionally, more questions
regarding what other physiological mechanism of plasma lipid regulation, TRIB1 could be
affecting remained unanswered.
The first goal of my dissertation was to explore possible physiological mechanisms by
which hepatic TRIB1 regulates plasma lipids. Using a Trib1 hepatocyte-specific knockout
model, I confirmed the previously published increased in total cholesterol, HDL cholesterol
and non-HDL cholesterol in mice and demonstrated that challenging these mice with WTD
(high fat, high carbohydrate) further exacerbated these phenotypes (Figure 3.2). However,
we were not able to observe changes in plasma triglyceride levels in any of the diets, a
phenotype that has been previously reported. Our results did suggest that Trib1Δhep mice
accumulate total cholesterol and triglycerides on the LDL lipoprotein fractions, and that
they have increased apoB protein levels, the main apolipoprotein in LDL (Figures 3.4-3.6).
Our studies also demonstrated that hepatic deletion of Trib1 in mice impairs postprandial
lipemia, which is likely leading to accumulation of triglycerides in the LDL lipoprotein
fractions, and that the accumulation of total cholesterol in the LDL lipoprotein fractions
Trib1Δhep mice is due to the improper catabolism of LDL and VLDL lipoproteins due to a
decrease of the Ldlr mRNA and protein levels (Figures 3.8-3.11). I further explore the
effects of hepatic trib1 on plasma lipids using an Ldlr KO mouse model and I demonstrated
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that hepatic Trib1 is able to regulate the clearance of apoB containing lipoproteins through
its regulation of LDLR, but that steady state plasma lipids are regulated independently of
the LDLR, specifically through the secretion of apoB containing lipoproteins from the liver
(Figures 3.12-3.14).
The results from our newly synthesized apoB secretion studies showed that Trib1Δhep mice
have increased secretion of apoB containing lipoproteins with no changes in triglyceride
secretion, which suggest that hepatic deletion of Trib1 leads to the secretion of triglyceride
depleted apoB containing lipoproteins (Figure 3.14). This is a novel finding that has not
been previously reported in any model study for hepatic lipoprotein secretion. Usually, an
increased secretion in apoB protein is accompanied by increased triglyceride secretion,
or there is increased triglyceride secretion with no changes in apoB protein, which means
that the lipoproteins secreted are lipid rich [147]. This is because the secretion of VLDLapoB from the liver is a tightly regulated process by the Endoplasmic-reticulum-associated
protein degradation (ERAD) complex, which targets improperly folded or improperly
lipidated apoB proteins for ubiquitination and proteasomal degradation [204]. My data
shows that Trib1Δhep mice have increased levels of triglycerides in their hepatocytes,
however this triglyceride is not being incorporated into the newly formed VLDL particles
(Figures 3.7, 3.14).
The findings from these studies are fascinating and future studies will aim to elucidate the
mechanisms that lead to these phenotypes. Because the ER stress response is highly
important in the regulation of VLDL-apoB secretion, I measured for changes in ER stress
markers such as pEF2a and observed that this was increased in Trib1Δhep mice. It is
possible that changes in the increased hepatic lipogenesis and hepatic steatosis
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development in Trib1Δhep mice are causing increased ER stress, which has been shown
to affect the rates of lipoprotein secretion from the liver [147], however, more studies would
be necessary to determine the mechanism of this effect and what other genes might be
involve in this regulation. Additionally, the development of hepatic steatosis mediated by
Trib1 deletion is a process that has not been fully studied. Increased CEBPa protein in
Trib1Δhep mice leads to increase de novo lipogenesis and increased liver lipids, however,
other players might be affecting this phenotype but have not been fully described in in vivo
models. Some examples previously mentioned included HNF4a, SIN3A and ERK1/2 [132,
133, 136, 137] and elucidating the molecular mechanisms by TRIB1 is regulating these
genes in vivo and their effects on plasma lipids and cardiovascular disease, will further
share light into all the potential mechanism by which TRIB1 is regulating multiple
cardiometabolic traits.
My experiments in Trib1Δhep mice also revealed that they are resistant to diet induced
obesity even though they develop hyperlipidemia (Figure 3.7). Previous research has
suggested that reduced expression of Trib1 in white adipose tissue (WAT), leads impaired
cytokine gene expression which protects the mice from weight gain and adiposity when
fed a high fat diet [149], however the effects of hepatocyte specific Trib1 deletion on
obesity are novel. It is crucial to determine the effects of hepatic Trib1 deletion on cytokine
expression and inflammation, which could help determining the mechanism by which
these mice are resistant to diet induced obesity, as well as it could help explain the
mechanism by which hepatic deletion of Trib1 leads to the development of hepatic
steatosis, a disease that is characterize by inflammatory responses and cytokine release.
If changes in inflammatory responses and cytokine release are not responsible for the
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differences in body weight in response to diet in Trib1Δhep mice, it is possible that these
phenotypes are cause by different patterns of food consumption or energy expenditure in
these mice, which could be determine by performing in vivo behavioral and metabolic
experiment in these mice. These experiments will help determine if Trib1Δhep mice are
consuming less food or if they are having the same nutrient intake, but expend more
energy compared to control mice.
Overall, the main next question resulting from our studies was determining the molecular
mechanism by which hepatic Trib1 regulates the LDLR. Because Trib1 has an established
role in regulating the transcription factor CEBPa by targeting it for ubiquitination and
proteasomal degradation, we decided to explore if Trib1 effects on plasma lipids and LDLR
regulation are mediated dependently or independently of CEBPa regulation. To do this,
we crossed our Trib1flox;flox mice to an Cebpaflox;flox with the goal of creating a double
knockout mice after injection with AAV-CRE (Trib1Δhep;CepbaΔhep/ DKO mice). The results
from my studies showed that simultaneous deletion of Cebpa in Trib1Δhep mice eliminated
the effects of hepatic deletion of Trib1 on plasma lipids, hepatic lipids, ALTs, triglyceride
catabolism, apoB catabolism and hepatic LDLR regulation, suggesting that increased
CEBPa protein is necessary for the effects of hepatic Trib1 deletion (Figures 4.2-4.6). We
also identified the Activating Transcription Factor 3 (Atf3) as a possible target mediating
Trib1’s CEBPa dependent regulation of the LDLR (Figures 4.9, 4.11-4.12). ATF3 is a
stress-inducible transcriptional repressor that has been shown to interact with the
promoter region of LDLR and represses its expression; furthermore, ATF3 directly binds
to the CEBPA protein [164, 166, 167]. Our RNA sequencing analysis showed that ATF3
was highly upregulated in the livers of Trib1Δhep but not in DKO mice, which was confirmed
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by qPCR and western blot (Figure 4.11). We also demonstrated that downregulating Atf3
in Trib1Δhep mice reduced the levels of total cholesterol, HDL- cholesterol and LDLcholesterol, and partially attenuated the effects on the LDLR (Figures 4.13-4.16).
The results from these studies suggested a partial effect of ATF3 downregulation
mediating a decrease in plasma lipids and increased LDLR protein, which might be due
to several reasons. We performed this siRNA knockdown pilot experiment once using the
highest dose recommended by the manufacturer, however Atf3 mRNA expression and
protein levels were not fully knockdown (Figure 4.13), suggesting we might need a higher
dose to achieve proper knockdown and observe more striking phenotypes. Additionally,
we could acquire an Atf3 knockout mice line and cross it to our Trib1flox;flox mice, which will
ensure complete lack of expression of Atf3. In both models, it would be crucial to perform
oral fat tolerance test, LDL and VLDL apoB kinetics and apoB secretion studies, which
would give us more concise answers as to what is the involvement of Atf3 in the regulation
of plasma lipids and LDLR in Trib1Δhep mice. It is also possible that Atf3 itself is not the
only factor contributing to Trib1 regulation of plasma lipid and the LDLR in a CEBPa
dependent manner, and that other factors are also involved in this regulation. If that is the
case, we will use the results from our RNA sequencing experiments for further identify
other mechanistic links by which hepatic Trib1 deletion is leading to the regulation of apoB
catabolism and the LDLR.
In these studies, I also compared our results to CepbaΔhep mice, which showed that Cebpa
deletion by itself decreases plasma lipids and plasma LDL in the cholesterol and
triglycerides fractions, had improved triglyceride clearance after fat load and had no
differences in VLDL or LDL apoB clearance (Figures 4.2- 4.6). These results confirm the
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fact that Cebpa is highly involved in the regulation of plasma lipids and provide us with a
model for further studying Cebpa hepatic deletion effects independently of its Trib1
regulation.
The third goal of this dissertation was to explore the physiological mechanism by which
Trib1 whole body deletion on a pure C57BL/6 background leads to a highly penetrant
lethal phenotype in mice. Our studies determined that Trib1 KO mice develop normally in
uterus and that the period of lethality was post-natal, between day 0 and day 1 after birth,
likely due to severely low blood glucose levels compared to control mice. The decrease in
glucose levels was accompanied by decrease glycogen and lactate levels, both of which
are substrates for glucose production by glycogenolysis and gluconeogenesis,
respectively (Figures 5.1- 5.2). Cebpa deficient mice die postnatally due to severely low
levels of hepatic glycogen [127], so it is possible that the decreased in hepatic glycogen
combined with decreased plasma lactate are causing or contributing to the severe
hypoglycemic phenotype in Trib1 KO neonates. In the future we will be performing
glycogen staining in the livers of Trib1 KO neonate mice to further characterize this
phenotype, if the changes are drastically different comparing Trib1 KO mice to control and
het mice, it is likely that this might explain the severe hypoglycemia in Trib1 KO mice. If
we don’t observed differences in hepatic glycogen content, we would consider measuring
plasma insulin levels again in these mice, as it has been broadly demonstrated that high
levels of insulin (hyperinsulinemia) can lead to severe hypoglycemia and neonatal death
[202, 205-209]. In our studies we also determined that about 5% of Trib1 KO mouse
survive the neonatal lethally period and make it to adulthood, and that similar to Trib1hep
mice, adult Trib1 KO have increased plasma lipids and impaired postprandial lipemia
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(Figures 5.5-5.6). I also demonstrated that Trib1 KO mice have decreased glucose levels
depending on their fasting time, and that their glucose and insulin tolerance is improved
compared to wild type and heterozygous mice (Figures 5.7- 5.8). Trib1hep mice also had
improved glucose tolerance with no changes in insulin tolerance (Figure 5.9).
The results from these studies suggest that additional to regulating plasma lipids, Trib1 is
involved in the regulation of glucose metabolism, an association that has not been
previously reported. In humans, cardiovascular diseases and high concentration of lipids
are associated/correlated with the development of type 2 diabetes (T2D), which is
characterized by increased plasma glucose levels due to decrease insulin or impaired
insulin sensitivity [210]. Our results showed that even though Trib1 KO mice are
characterized by increased lipids, their glucose and insulin tolerance is improved, which
are phenotypes that are protective against the development of T2D in humans. These
findings are striking and present a novel association of Trib1 with another cardiometabolic
trait associated with disease. To determining the molecular mechanisms by which Trib1
is regulating glucose metabolism genes, we should perform RNA sequencing studies in
tissues such as the liver and pancreas from these mice, both of which are critical in the
regulation of plasma glucose in mammals. The results from these studies will provide with
an array of unbiased targets which could explain how Trib1 deletion is leading to changes
in glucose metabolism and neonatal lethality in mice.
In summary, I have shown that Trib1 plays a crucial role mediating the regulation of
multiple physiological pathways that regulate plasma lipid metabolism, all of which are
associated with the development of cardiometabolic disease. Additionally, my studies
have opened future paths of investigation of Trib1 and other novel cardiometabolic traits
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such glucose metabolism and T2D, both of which have not been previously described.
Overall, the results from my studies highlight the fact GWAS findings combined with
experimental validation can lead to novel biological insights and better understanding of
how natural genetic variation can impact human disease.
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APPENDIX

Hepatocyte deletion of Trib1 leads to the plasma secretion of an unidentified
protein of approximately 20 kDA.
While performing the newly synthesized apoB secretion experiments, I discovered that
plasma from Trib1Δhep mice contains a prominent protein band visible by autoradiography
between the molecular weight markers of 15-25kD (Figure 6.1 A). The relative abundance
of this protein was significantly higher in Trib1Δhep plasma compared to control mice (Figure
6.1 B). Additionally, this unidentified protein was visible by Ponceau S staining in plasma
from 4 hour-fasted Trib1Δhep mice, but was very minimally or not expressed in control mice
(Figure 6.1 C). To further investigate the identity and possible role of this protein with Trib1
effects on plasma lipids, we performed Mass Spectrometry on the bands of interest. We
submitted a Coomassie stained gel containing Control and Trib1Δhep samples loaded in
equal volumes (Figure 6.1 D) and tested one sample of each condition as an initial
exploratory approach. Interestingly, the assay identified 116 proteins in samples from
control and 126 proteins in samples from Trib1Δhep mice (Figure 6.1 E), with not all of them
matching the size range of the visualized protein bands. We identified 23 proteins that
were approximately the same molecular weight as the visualized bands, and that were
more abundant in Trib1Δhep mice (Table 3). A pivotal result from this pilot study was the
increased abundance of the Mayor Urinary Protein (MUPs) family, specifically MUP 1, 2,
3 AND 17. More interesting, several MUPs family members are also increased at the
mRNA level in Trib1Δhep mice based on the RNA Seq data, including Mup 2, 6, 8, 9, 17 and
others. MUPs are a subfamily of proteins synthesized in the liver, secreted through the
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kidneys, and excreted in urine [211, 212]. MUPS are present in many species, however
they are not conserved in humans, which presents a challenge in translating these findings
to any human disease significance [213].
Another limitation of this study is that the results are results are based on a pilot study
from only one sample. We would need to repeat this study with additional biological
replicates to confirm the results and to gain more confidence in the possible identity of the
protein. Another way of reducing nonspecific detection of proteins is to use depletion
columns for highly expressed plasma proteins such as Albumin and IgGs. This will ensure
higher detection of smaller, lower expressed proteins. In the case that we identify other
highly represented proteins, or that MUPs are still the most represented upregulated
proteins, follow up studies would be necessary to corroborate their identity, such as
western blots.
To investigate the relevance of this unidentified protein in humans, we could acquire
plasma samples from human carriers of TRIB1 mutations and perform Coomassie staining
as I did for the mouse samples. In the case that this band is also present in human
samples, it would suggest that the protein is not a MUP and that it might be biologically
important in the regulation of lipids in humans too. These samples could also be used for
mass spectrometry as well proteomic analysis with the goal of identifying the specific
protein of interest.

142

Figure 6. 1. Trib1Δhep mice secrete an unidentified protein of around 15-25 kDA.

Trib1

hep

Trib1 hep

Trib1 hep

ri 1

hep

Figure 6.1: A. Autoradiography of plasma from Trib1Δhep and control mice 60 minutes after
injection with 35S-met/cis and pluronic injection. B. Quantification of an unidentified protein
counts normalized to total precipitable protein count. C. Ponceu staining of 4hr fasted
plasma from Trib1Δhep and control mice. D. Coomassie blue staining of 4hr fasted plasma
from Trib1Δhep and control mice of samples that were submitted for mass spectrometry
analysis. E. summary table of mass spectrometry results analysis.
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Table 3. Selected mass spectrometry results based on the size of the unidentified
protein band and higher abundance on Trib1Δhep vs control mice
Protein

MW
kDa

Coverag
e%

Abundance
- Control

Abundance
- Trib1
LSKO

Relative
AbundanceTrib1
LSKO/Control

Mucin-like protein
2

14.8

9

9933

76938

7.7

Serum amyloid A4 protein

15.1

27

3384727

5102911

1.5

Ig heavy chain V
region 93G7

15.5

10

93191

129524

1.4

Transthyretin

15.8

41

190931699

315554829

1.7

Lysozyme c-1

16.8

8

243167

309396

1.3

Immunoglobulin J
chain

18

21

2467437

32156859

13.0

cathelicidin
antimicrobial
peptide

19.4

22

202945

490280

2.4

Actin-related
protein 2/3
complex subunit 4

19.7

14

664496

1139557

1.7

Major urinary
protein 1

20.6

67

60925563

324867934

5.3

Major urinary
protein 17

20.6

16

16813090

132962899

7.9

Major urinary
protein 2

20.7

73

231285

2307170

10.0

Cerebellin-1

21.1

4

189533

449446

2.4

apolipoprotein M

21.3

36

38194963

50579485

1.3

Major urinary
protein 3

21.5

11

156851

546053

3.5
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Angiopoietin-like
protein 8

22.1

5

0

34584

100.0

Receptor
expressionenhancing protein
6

22.2

6

0

34542

100.0

Secreted
phosphoprotein
24

23.1

6

116479

464715

4.0

Retinol-binding
protein 4

23.2

37

121482728

272297637

2.2

Alpha-1-acid
glycoprotein 3

24.1

10

0

196940

100.0

BPI foldcontaining family
A member 2

24.7

6

29887

161626

5.4

Glutathione
peroxidase 3

25.4

21

1034408

4396303

4.3

Proteasome
subunit beta type6

25.4

5

11754

589704

50.2

Complement C1q
subcomponent
subunit A

26

6

47896

92993

1.9
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